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Abstract 
Human Immunodeficiency Virus Type 1 (HIV-1) is the causative agent of 
Acquired Immunodeficiency Syndrome (AIDS), currently the leading cause of death 
from infectious diseases. Since HIV-1 co-opts the host cellular machinery, the study of 
cellular factors involved is a rational approach in discovering novel therapeutic targets for 
AIDS drug development. In this thesis, we present studies on two such proteins. 
APOBEC3G is from the family of cytidine deaminases known to keep 
endogenous retroviruses and retrotransposons at bay to maintain stability of the human 
genome. APOBEC3G targets Vif-deficient HIV-1 particles and renders them non-
infectious, partially through deaminase-dependent hypermutation of the provirus during 
reverse transcription. APOBEC3G largely localizes in mRNA processing (P) bodies, 
cytoplasmic structures involved in RNA metabolism. Here we explore the significance of 
APOBEC3G localization in P bodies. We found that disrupting P bodies does not affect 
virion incorporation of endogenous APOBEC3G, implying that the APOBEC3G fraction 
in P bodies is not directly involved in the production of nascent, non-infectious particles. 
We also study UPF1, another host protein encapsidated by HIV-1. It is an 
essential protein mainly studied for its role in nonsense-mediated decay (NMD) pathway 
and belongs to the same helicase superfamily as MOV10, a recently identified antiviral 
factor. We found that UPF1 is incorporated in HIV-1 virions in a nucleocapsid-dependent 
manner and is required for single-cycle infectivity at an early, post-entry step of the viral 
life cycle. This novel function of UPF1 most likely does not involve NMD since 
depletion of UPF2 does not affect viral infectivity. 
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CHAPTER I: Introduction 
Studies on cellular host factors involved in the HIV-1 life cycle 
 
A. HIV-1/AIDS: Looking back 
“…finding the cause of a disease is the alpha but not the omega of its 
eradication.” -R. Gallo and L. Montagnier, NEJM 2003 (Gallo 2003) 
 
1. An epidemic at the turn of the century 
Between 1979 and 1981, more than a hundred young men from New York and 
California sought medical attention for violet-colored skin lesions, enlarged lymph nodes, 
and pneumonia (CDC 1981b). They were diagnosed with multiple opportunistic 
infections (bacterial, viral, and fungal) and 40% of reported cases were fatal (CDC 
1981a). Epidemiologists from the Center for Disease Control and Prevention (CDC) 
chronicled the patients’ characteristics (CDC 1981a) as Caucasian, aged 25-49, and 
homosexual or bisexual. Following these was another CDC report describing a cohort of 
Haitians living in the United States who also manifested opportunistic infections and 
Kaposi’s sarcoma (CDC 1981a). A third group that emerged were male, heterosexual 
patients diagnosed with hemophilias requiring frequent transfusions of blood products 
and who died of Pneumocystis carinii pneumonias (CDC 1982b). The clustering of all 
groups’ diagnoses (Kaposi’s sarcoma skin lesions and P. carinii pneumonia) pointed 
towards an immunocompromised patient, such as those seen in patients on 
immunosuppressive therapy after a liver transplant. The CDC tested patient blood 
4
specimens and found marked decreases in their levels of CD4+ T helper cells. This 
disease manifesting as multi-systemic opportunistic infections was eventually called 
Acquired Immune Deficiency Syndrome (AIDS) (CDC 1982a). 
 
2. The Human Immunodeficiency Virus Type 1 (HIV-1) is the causative agent 
of AIDS 
A few years prior to the emergence of AIDS, Robert Gallo and his group at the 
National Institutes of Health had identified the first human retrovirus, the Human T cell 
Lymphotropic Virus Type I (HTLV-1) (Poiesz et al. 1980), which is associated with adult 
T cell leukemia-lymphoma. Since one of the biomarkers of HTLV-1 infection is 
depressed CD4+ T cell levels, R. Gallo proposed that HTLV-1 or -2 causes AIDS (Gallo 
and Montagnier 1987) during the 1983 Cold Spring Harbor Workshop on AIDS. A few 
months later, R. Gallo’s collaborator, Luc Montagnier, and his colleagues published in 
Science their findings isolating and identifying a non-transforming retrovirus which they 
dubbed "lymphadenopathy associated virus" (LAV), since the etiologic agent was 
isolated from lymph nodes of AIDS patients (Barré-Sinoussi et al. 1983). This was later 
renamed “HIV-1”. Although the discovery of the AIDS causative agent was initially 
contentious, the US and French governments have agreed to acknowledge Gallo's and 
Montagnier’s groups as co-discoverers and to share the intellectual properties associated 
with the discoveries (Vahlne 2009). In 2008, Montagnier and Barre-Sinoussi received the 
Nobel Prize for Medicine for their seminal work in the discovery of HIV-1 (Cohen and 
Enserink 2008). 
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B. HIV-1/AIDS: Looking forward 
“…is there really hope of achieving the vision of an AIDS-free generation?”  
– Salim S. Abdool Karim (CAPRISA 004 trial co-author), Science 2012 (Abdool 
Karim 2012)  
 
1. HIV/AIDS still the world’s top infectious killer  
Today, AIDS remains the world’s leading infectious killer, with 30 million to date 
succumbing to its multi-systemic effects.  WHO 2010 statistics show that 34 million are 
currently living with HIV-1, with 2.7 million newly infected cases in 2010.  These 
numbers, though, are starting to plateau in most countries due to prevention programs and 
availability of treatment, with some exceptions in eastern Europe and Central Asia 
(Cohen 2010).  
2. More accessible testing for HIV-1  
Widespread public health efforts have fought the initial stigma for HIV-1 testing. 
Now, it is routinely offered in the outpatient clinics. Also, quantitative PCR protocols 
have been developed for faster and more sensitive diagnosis, compared to the ELISA-
based test. Last July 2012, the Food and Drug Administration (FDA) approved the 
OraQuick In-Home HIV Test, the first over-the-counter diagnostic kit that can detect 
antibodies against the virus from a saliva sample, providing results in less than an hour 
(Chappelle 2012).  
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3. Improved prognosis for HIV-1/AIDS patients  
Today, the diagnosis of “HIV-1 positive” is no longer a death sentence. With several 
drug regimens now available, the life expectancy of AIDS patients has increased. The 
highly active antiretroviral therapy (HAART) is a drug regimen initiated when HIV-1 
positive patients’ CD4+ T cell counts fall below 500/µL (Writing Committee for the 
CASCADE Collaboration 2011). Starting and maintaining the regimen improves the 
prognosis for HIV-1 infected patients by delaying disease progression.  
The process of HIV-1 replication is error-prone, with several quasispecies existing at 
the same time in the same patient. Since HIV-1 develops drug resistance quickly due to 
low-fidelity reverse transcription and recombination, the aim of HAART is to suppress 
viral replication to very low levels by using 3 or more drugs targeting different steps of 
the viral life cycle, thereby preventing the emergence of drug-resistant viruses. This still 
remains challenging due to the development of drug-resistant viruses in patients who 
have higher viral loads. 
 
4. Vaccine trials and prophylaxis regimens  
The search for an HIV-1 vaccine has been a tortuous road, primarily because 
traditional vaccine approaches have not worked. A live attenuated virus may mutate to a 
pathogenic strain, since HIV-1 has the propensity to mutate quickly. Also, an inactivated 
virus or protein-based vaccines do not generate any effective antibodies. Broadly 
neutralizing antibodies, which would react to a wide range of HIV-1 strains, have shown 
promising results in primate models. However, clinical trials such as the Microgenesis 
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and Vaxgen studies failed to elicit the broad response needed to tackle a genetically 
variable virus (Sekaly 2008). 
The focus then shifted to eliciting a robust T cell response by using replication 
defective adenoviral vectors (Sekaly 2008). Promising results were seen in a limited 
numbers of macaques (Burton et al. 2004). Novel vaccine regimens that were studied 
included DNA vectors expressing viral proteins to prime the immune response and a 
replication-defective recombinant adenovirus serotype 5 (rAd5) vector to boost responses 
(Robinson and Weinhold 2006).  Phase I clinical trials have been published from related 
NIH Vaccine Research study groups (Graham et al. 2006; Catanzaro et al. 2006). 
The “prime-boost” strategy was also utilized by Merck and Company when they 
began the international STEP trial. However, the study was suspended after an interim 
review in 2007 showed no efficacy (http://www.hvtn.org/science/1107.html). After 
further analysis, the Merck STEP trial revealed a disturbing trend towards enhancement 
of HIV-1 infection among vaccine recipients, especially those with elevated adenoviral 
immunity at the start of the study (Cohen 2007). The statistical analyses were confusing 
because, while the P values showed were statistically significant, these analyses may not 
be appropriate for the study since the “study was not designed to assess potential harm,”  
cautioned S. Self, chief statistician of the HIV Vaccine Trial Network (Cohen 2007). 
The first promising study in the field was the RV144 vaccine trial in Thailand, which 
only showed a modest protection: 31.2% decrease in new infections among vaccine 
recipients (Pitisuttithum et al. 2011). The vaccine consisted of canarypox vectors (prime) 
and recombinant gp160 or gp120 (boost) which aimed to induce cell-mediated immune 
8
responses while significantly enhancing antibody responses in HIV-uninfected volunteers 
(Pitisuttithum et al. 2011). However, the resulting immune responses were not as robust 
as the researchers expected. Still, the modest protection has been praised as a step in the 
right direction, and several independent groups continue to study the RV144 samples to 
glean new correlates of protection (Cohen 2009). 
An alternative to the HIV-1 vaccine conundrum is the administration of pre-exposure 
prophylaxis to high-risk populations. Pre-exposure prophylaxis for HIV-1 with Truvada 
(combined tenofovir and emtricitabine) has recently been approved by the FDA 
(Jefferson 2012). The iPREx trial showed that the Truvada treatment group had 44% 
fewer infections after 1.2 years of daily oral intake of the prophylactic drug among men 
and transgender women who have sex with men (Grant et al. 2010). However, the FEM-
PrEP trial, a related study for Truvada prophylaxis among women, was suspended in 
April 2011 due to lack of efficacy (van Damme et al. 2012). Blood tests to confirm 
compliance with daily drug intake showed that only 26% of the participants who became 
HIV-1 positive (i.e. seroconverted) and 35% of the uninfected participants had optimal 
target levels of the drug, suggesting that FEM-PrEP study participants did not adhere to 
dosing schedules (van Damme et al. 2012). In a third related study on HIV-1 
serodiscordant couples (one partner was HIV-1 positive and the other was not), called the 
Partners PrEP trial, Truvada prophylaxis showed a 75% relative reduction of infection 
compared to the placebo group (Baeten et al. 2012). In this study, only 31% of 
participants who seroconverted had target-levels of the drug while 82 % of uninfected 
participants had the desired drug levels (Baeten et al. 2012).  L. Van Damme and 
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colleagues of the FEM-PrEP trial postulate that differences in the biology of men and 
women with regards to drug responses or HIV-1 susceptibility can be overcome by 
increased adherence to prophylaxis intake (van Damme et al. 2012). The Truvada 
projects, which reportedly cost $43.6 M, were supported by the National Institutes of 
Health and the Bill and Melinda Gates Foundation.  
 
5. A patient is cured 
Timothy Ray Brown (a.k.a. “The Berlin Patient”) was an AIDS patient diagnosed 
with acute myelogenous leukemia. He received an experimental therapy envisioned by 
hematologist-oncologist Gero Hütter (Cohen 2011), consisting of a bone marrow 
transplant from a donor with !32 CCR5, a polymorphism of the co-receptor which is 
protective against HIV-1 entry (Liu et al. 1996; Samson et al. 1996). Currently, Mr. 
Brown has no detectable virus in his system (Cohen 2011). J. Lalezari of Quest Research 
and R. Mitsuyasu from UCLA embarked on a gene therapy-based clinical trial to 
determine whether this cure is reproducible. The collaborative study is ongoing and the 
researchers presented their preliminary data at the 2011 Conference of Retroviruses and 
Opportunistic Infections (Cohen 2011). 
C. HIV-1 Life Cycle  
1. Overview 
HIV-1 belongs to the Retroviridae family and exhibits the characteristic retroviral life 
cycle, which involves reverse transcription of the viral RNA genome to DNA and its 
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insertion into the host genome (see Figure 1.1A). The HIV-1 genome is ~9kb, encoding 
for three polyproteins and several regulatory and accessory proteins (Frankel and Young 
1998). The expression of Gag is sufficient to drive the formation and release of virus-like 
particles from the host cell (Freed 1998), making it the primary viral polyprotein for viral 
assembly. Gag is translated as polyprotein Pr55 and is processed by the viral protease 
(PR) during viral particle maturation into the matrix (MA), capsid (CA), nucleocapsid 
(NC), p6 and spacer peptides (SP1, SP2) (see Figure 1.2). MA is associated with the 
inner membrane of the viral particle, while CA forms a shell around the NC in complex 
with the viral RNA genome. The other major viral polyproteins are Gag-Pol, which 
autocatalyses into PR, reverse transcriptase (RT), and integrase (IN), and Env (gp160), 
which is processed by cellular proteases (furin or furin-like proteases) into gp120 (surface 
protein, SU) and gp41(transmembrane protein, TM). Viral proteins Tat and Rev function 
in viral transcription and viral RNA export, respectively. Viral accessory proteins such as 
Vif, Vpr, Vpu and Nef are usually required to overcome cellular restriction factors.  
 
2. Binding to host receptors and viral entry 
As the virus docks on its target cell, the viral envelope binds the host receptor CD4, 
which is necessary for infection (Dalgleish et al. 1984). This binding induces a 
conformational change in the viral envelope (Sattentau and Moore 1991), promoting an 
association with co-receptors (Ugolini et al. 1997). After this conformational change in 
the viral envelope, it is now able to bind the chemokine receptors CCR5 (Deng et al. 
1996; Dragic et al. 1996) or CXCR4/fusin (Feng et al. 1996), which are required for viral  
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Figure 1.1 The HIV-1 Life Cycle. HIV-1 is a lentivirus that uses CD4 as a primary 
receptor and either CXCR4 or CCR5 as co-receptor. The virus enters the host cell via 
fusion or endocytosis. The viral core, containing two copies of the RNA genome, is 
released into the cytoplasm. Upon completion of reverse transcription, the pre-integration 
complex is imported to the nucleus, where it is integrated into the host genome. 
Transcription of the provirus proceeds with Pol II and tat transactivation. The viral 
proteins are subsequently translated and the nascent virions assemble on the membrane. 
These bud, and subsequent processing of viral proteins by viral protease transforms the 
immature virion to a mature, infectious virion. 
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Figure 1.2 HIV-1 Viral Proteins. HIV-1 translates three polyproteins: 1) Gag/Pr55 
(processed by viral protease into MA, CA, NC, p6, and two spacer peptides), 2) Gag-Pol 
(autocatalyses to protease, reverse transcriptase, and integrase), 3) Env/gp160 (processed 
by cellular proteases into gp120 and gp41). HIV-1 also encodes regulatory proteins Tat 
and Rev and accessory proteins Vif, Vpu, Vpr, and Nef. 
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entry (Clapham and Weiss 1997). The binding of gp120 to CD4 and the co-receptor 
causes a conformational change in gp41, exposing a fusion peptide that facilitates entry 
into the target cell. Viral entry occurs via membrane fusion at the plasma membrane or 
after endocytosis (Daecke et al. 2005; Miyauchi et al. 2009). As mentioned above, 
individuals homozygous for the !32 CCR5 polymorphism are highly resistant to HIV-1 
infection (Liu et al. 1996; Samson et al. 1996). 
In 2003, the FDA approved enfurvitide/T-20 (Fuzeon), the first entry inhibitor 
drug (Robertson 2003).  The mechanism of action of enfurvitide is two-fold: it blocks the 
gp120-CD4 complex from interacting with the CXCR4 co-receptor, and it also targets the 
gp41 pre-hairpin conformation (Ashkenazi et al. 2011; Kilby et al. 1998). Newer drugs in 
this class have been categorized as follows: 1) attachment inhibitors, 2) co-receptor 
binding inhibitors, and 3) fusion inhibitors (Ashkenazi et al. 2011). 
 
3. Uncoating and reverse transcription 
Once the virion enters the cell, it undergoes uncoating and reverse transcription. The 
viral uncoating step involves dissociation of CA units to release the NC-RNA complex. 
Uncoating can occur in vitro upon synthesis of full-length viral DNA (vDNA) by the 
virion core-associated RT, suggesting that any cellular factors required for uncoating are 
present within HIV-1 virions (Arhel et al. 2007). Reverse transcription may initiate inside 
the core prior to entry, but uncoating has to occur for reverse transcription to proceed. 
The completion of reverse transcription and the formation of the central DNA flap trigger 
or facilitate uncoating (Arhel et al. 2007). Conversely, unsuccessful reverse transcription 
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(e.g. by using RT inhibitor Nevirapine or a DNA flap mutant) prevents uncoating (Arhel 
et al. 2007). The following models for uncoating have been put forth (Arhel 2010): 
• Quick uncoating: due to a change in CA amounts, from high concentration inside 
the virion to low concentration in the cytoplasm, the viral core disassembly occurs 
immediately after delivery of the viral core to the cytoplasm  
• Slow uncoating: the viral core remains intact after entry, but slowly disassembles 
as reverse transcription proceeds, with the resulting viral cDNA and associated 
proteins being transported to the nuclear periphery 
• Uncoating at the nuclear pore: viral core disassembly occurs at the nuclear pore 
prior to nuclear import to keep the reverse transcriptase enzyme associated with 
the viral genome 
The reverse transcription complex (RTC) is the viral nucleoprotein complex 
undergoing reverse transcription to yield double-stranded viral DNA from the viral RNA 
genome. The efficiency of reverse transcription is reported to be ~30% (Thomas et al. 
2007). The steps of reverse transcription are as follows (see Figure 1.3): 
i. Synthesis of minus strand: reverse transcriptase catalyzes the minus-strand using a 
cellular tRNA primer annealed to the primer binding site (PBS) near the 5’ end of 
the viral genome. Reverse transcriptase extends the minus strand towards the 5’ 
end of the genome, including the unique 5’ (U5) genomic sequence and the 5’ 
repeat (R) sequence (identical sequences found near the 5’ and 3’ end of the viral 
genome). While the reverse transcriptase extends the primer, the RNase H activity 
of the reverse transcriptase also degrades the genomic RNA in the RNA-DNA 
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hybrid, with the exception of the polypurine tract (PPT) at the central and 3’ 
positions 
ii. Minus-strand strong stop: occurs once the reverse transcriptase reaches the 5’-
most end of the genome 
iii. First strand transfer: the minus-strand moves to the 3’ end of the second copy of 
the viral genome, annealing at the 3’ R sequence; reverse transcription proceeds 
towards the 5’ end with the reconstitution of the unique 3’ (U3) sequence next to 
the R sequence, the coding region, and the PBS; recombination for vDNA occurs 
during this intermolecular strand transfer step  
iv. The PPT (cPPT and 3’PPT) primes the plus strand synthesis, using the minus 
strand as the template 
v. Second strand transfer: the plus strand moves towards the 5’end of the minus 
strand and extends the plus strand. The 3’PPT primed-plus strand extension 
occurs through the cPPT and ends downstream at the central termination 
sequence, forming an overlap called the central DNA flap 
 
As reverse transcription is completed, the RTC is transported from the entry point to 
the nucleus. These complexes move rapidly toward the nuclear compartment, using 
microtubules and actin filaments to reach the nuclear pore, as seen in fluorescently-
labeled HIV-1 cores which traffic along microtubules (Arhel et al. 2006; McDonald et 
al.). However, a kinetics study showed that inhibitors of the cytoskeleton do not totally 
block transport of the RTC to the nucleus, suggesting that actin is not required for
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Figure 1.3 Steps in HIV-1 reverse transcription. (A) Reverse transcription is initiated 
by tRNALys annealed to the primer binding site (PBS) and extended towards the 5’ end of 
the genome. (B) The minus strand jumps from the 5’ end to the 3’ end of the genome, 
with base pairing occurring in the repeat (R) region. This jump may also occur from one 
RNA copy to the other. (C) Minus strand extension moves toward the 5’ end of the 
genome, reconstituting the PBS. (D) Initiation of plus strand polymerization occurs either 
at the cPPT or the 3’PPT, both of which remain intact after RNase H digestion (see 
below). The minus strand is used as the template. (E) The plus strand jumps to the 5’ end 
of the minus strand and extends the plus strand towards the 3’ end. (F) The 5’ and 3’ 
long-terminal repeats (LTRs) are completed. 
 
RNase H digestion: as reverse transcription proceeds, the RNase H activity of the reverse 
transcriptase degrades the RNA strand in the RNA-DNA pairing that is formed. 
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RTC movement (Arfi et al. 2009).  Also, some functional RTCs are lost during transport 
towards the nucleus (McDonald et al.). 
A comparison of the vDNA quantities produced within cells relative to the amount of 
viral RNA genomes in the inoculum shows that only 5% of virus particles present 
actually initiated reverse transcription, with 0.41% of the genomes proceeding all the way 
to a provirus (Thomas et al. 2007).  
The drug class of HIV-1 RT inhibitors is divided into non-nucleoside RT inhibitors 
(NNRTIs) and nucleoside RT inhibitors (NRTIs). NNRTIs (ex. Nevirapine) inhibit DNA 
polymerization by binding to an allosteric site, resulting in a conformational change in 
the active site of the reverse transcriptase and causing a decrease in its binding to 
nucleosides (Adams et al. 2010). NRTIs (ex. Zidovudine/AZT) are nucleotide mimics 
that lack the 3’OH. They compete with endogenous nucleotides and block further 
elongation by HIV-1 reverse transcriptase (Cihlar and Ray 2010). 
 
4. Nuclear import and integration 
The pre-integration complex (PIC) is composed of the vDNA, with associated viral 
and cellular proteins, after reverse transcription is completed. The PIC is transported into 
the nucleus through the nuclear pore and is integration-competent. The PIC sheds most of 
its CA (Fassati and Goff 2001; Miller et al. 1997), in contrast to the RTC discussed 
above. 
 The viral integrase (IN) is the third enzyme from the Gag-Pol polyprotein and it 
facilitates the insertion of the vDNA into the host genome by removing 2-3 nucleotides 
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on the 3’ end to produce a recessed end. IN also nicks the cellular target DNA and joins 
the viral 3’ recessed end to the 5’ overhang of cellular DNA. The cellular machinery 
performs gap repair to complete the integration process. At this point, the integrated 
vDNA is now called a provirus. 
Occasionally, vDNA forms episomes called 1-LTR circles (containing one copy 
of the long-terminal repeat, LTR, due to homologous recombination) or 2-LTR circles 
(has 2 copies of LTR joined end-to-end). These unintegrated forms may persist but are 
diluted out during cell division (Pierson et al. 2002; Butler et al. 2002).  
 The lens epithelium-derived growth factor (LEDGF, also called p75) is a nuclear 
transcription co-activator that tightly binds to IN (Cherepanov et al. 2004) and stabilizes 
IN (Llano et al. 2004). LEDGF activates IN and is required for provirus formation and 
infection (Emiliani et al. 2005; Llano et al. 2006) and also for the nuclear entry of PICs 
(Llano et al. 2004). LEDGF protects IN from degradation by the proteasome, but 
depletion of LEDGF does not affect HIV-1 infection efficiency (Ciuffi et al. 2005; 
Emiliani et al. 2005; Llano et al. 2004; 2006). 
The DNA damage response proteins have also been implicated in integration. 
Mutant cells undergo apoptotic cell death after viral infection (Daniel et al. 1999; Smith 
and Daniel 2006). These proteins do not seem to be directly involved in integration but 
probably fill single-stranded gaps and nicks after integration (Ariumi et al. 2005; Dehart 
et al. 2005). Other viral factors required for integration include NC, which enhances the 
efficiency of integration (Buckman et al. 2003; Gao et al. 2003), and the central DNA 
flap (Zennou et al. 2000).  
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In 2007, the FDA approved the first IN inhibitor, Raltegravir. This drug binds to the 
active site of IN, blocking its activity (Cocohoba and Dong 2008). The PIC is therefore 
unable to integrate into the host DNA, and is rendered noninfectious. Merck & Co. 
spearheaded the research on lead compounds, which led to the development of 
Raltegravir (Quashie et al. 2012).  
 
5. Transcription of provirus and export of viral RNA  
As mentioned above, the long-terminal repeat (LTR) is generated during reverse 
transcription and exists as repeats in the 5’ and 3’ ends of the viral DNA. In the context 
of integrated viral DNA, the major function of the LTR is the regulation of viral RNA 
synthesis. Expression from the HIV-1 LTR is trans-activated by Tat. Together with cyclin 
T1 and CDK9, Tat binds the RNA TAR element in nascent HIV-1 transcripts, directs the 
phosphorylation of RNA Pol II, and thereby improves its processivity (Yankulov and 
Bentley 1998).   
After transcription, both spliced and unspliced viral transcripts are transported to the 
cytoplasm. Rev (regulator of virion) facilitates the transport of unspliced and singly 
spliced viral RNA out of nucleus. Rev binds the structured RRE (Rev response element) 
and functions as an adaptor to link the viral RNA to the host protein export pathway. 
Viral RNA can be found in 3 forms. The 9kb RNA (unspliced) is translated into Gag 
and Gag-Pol, with the latter produced due to a frame shift in a slippery sequence. Two 
copies of the full-length Gag RNA are also incorporated as the genome of nascent virions 
(Butsch and Boris-Lawrie 2002). The 4kb RNA (partially spliced or singly spliced) codes 
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for Env, Vif, Vpu, and Vpr, while the 2kb RNA (multiply spliced) is translated into Rev, 
Tat, and Nef (Emerman and Malim 1998). The route of mRNA export from the nucleus 
predetermines the subsequent route of trafficking of Gag protein that is translated from 
that mRNA and host factors that interact with it (Swanson et al. 2004).
 
6. Translation of viral proteins and assembly of viral particles 
As mentioned above, Gag is translated as a polyprotein and is subsequently processed 
by the viral protease (PR) during viral particle maturation into MA, CA, NC, p6 and 
spacer peptides (Frankel and Young 1998). In immature virions, these are arranged 
radially, with MA found under viral envelope and NC found in the innermost portion of 
particle. As the virions mature, CA forms a shell around the NC, which is in complex 
with the viral RNA genome. This is visualized by electron microscopy as an 
electrodense, conical structure called the viral core. NC functions as a chaperone protein 
for the viral RNA genome. NC interacts with viral or cellular RNA nonspecifically, but 
has the propensity to package full-length viral RNA with the psi signal found in the 5’ 
region of the viral RNA. This psi signal is lost in spliced viral RNA. Not all viral 
particles contain RNA (Coffin et al. 1997). NC is substantially enriched relative to CA in 
preparations of purified viral cores (Welker et al. 2000; Forshey and Aiken 2003). 
 Several attempts have been made to estimate the Gag content in viral particles. 
Empirical determination of the ratio of viral genomic RNA to CA, which corresponds to 
∼104 virions pg–1 CA antigen (Piatak et al. 1993). In a study by S. Layne and colleagues 
linking CA concentration with the number of particles counted by thin-section EM 
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compared to a known standard, they estimate 1,200 ± 700 CA proteins per virion (Layne 
et al. 1992). In an independent study by P. Zhu and colleagues, they compared the 
concentrations of CA and Env proteins in purified virus preparations coupled with 
counting Env trimers per viral particle by negative stain EM, estimating 1,400 CA 
proteins per virion (Zhu et al. 2003).  
A newer report by J. Briggs et al. estimates ∼5,000 copies of Gag for an average 
immature HIV particle, while only 1,000-1,500 CA molecules comprise the mature viral 
core (Briggs et al. 2004). This implies that less than one-third of immature Gag 
contributes to the mature viral core and that a considerable amount of free CA may be 
found inside the viral particle (Briggs et al. 2004). Also, about one-third of viral particles 
have 2 cores but very few have 3 cores (Briggs et al. 2004). As for efficiency of infection, 
only one in eight virus particles that initiate an infection results in an integrated copy of 
the viral DNA in the host genome (Thomas et al. 2007). The ratio of infectious to 
noninfectious particles has been estimated to be between 1 in 1,000 and 1 in 60,000 
(Andreadis et al. 2000; Dimitrov et al. 1993; Kimpton and Emerman 1992; Marozsan et 
al. 2004).  However, infectivity may be underestimated because of cell-free viral particles 
not encountering a target cell. A recent study attempting to address this issue concluded 
that there is approximately 1 infectious particle in 8 to 20 viral particles (Thomas et al. 
2007). 
Aside from measuring Gag in viral particles, efforts have been made to 
characterize other components of the viral particle. An older report by J. Coffin estimates 
that 2,000 Gag (Pr55) molecules, along with 50 to 100 Gag-Pol precursor proteins, form 
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homodimers and then capture and encapsidate two copies of the viral RNA genome with 
about 20 copies of host tRNALys isoacceptors (tRNALys ) (Coffin et al. 1997). An 
estimated 40–100 IN molecules are encapsidated within each HIV particle (Pommier et 
al. 2005). Also, ~400 transmembrane glycoproteins (gp120 and gp41) trimers surround 
the nucleoprotein core (Vogt 1997). An average 145-nm immature HIV-1 virion would 
contain ∼700 molecules of Vpr, which would be 1:7 ratio compared with Gag (Müller et 
al. 2000).   
Since the maturation of virions is essential for viral infectivity, the viral PR has been 
a feasible drug target. First-generation protease inhibitors (P.I., e.g. Indinavir, Saquinavir, 
Nelfinavir) had significant side-effects and complicated dosing systems (Tejerina and 
Bernaldo de Quirós 2011). With newer P.I. (Darunavir/Ritonavir), monotherapy is a 
viable option for maintenance therapy once virological suppression is achieved 
(Estébanez and Arribas 2012). 
 
D. Cellular host factors 
Since viruses are, by their nature, obligate parasites, they hijack the cellular 
machinery to complete their life cycle. On the other hand, the cell has evolved factors 
which target and restrict the spread of infection. Therefore, increasing our knowledge of 
host factors that may be essential or may modulate steps in the viral life cycle leads to a 
better understanding of the host-pathogen relationship and of potential therapeutic targets 
(Goff 2007). 
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The last couple of years have seen the advent of genome-wide screens to identify 
candidate factors that may be “pro”-viral or antiviral. siRNA-based platforms facilitate 
genome-wide hunts for these “HIV-dependency factors”, first published by A. Brass and 
colleagues (Brass et al. 2008) and subsequently published by independent groups (König 
et al. 2008; Zhou et al. 2008). R. Konig, et al. have also used additional criteria, which 
they have dubbed “evidence score” and have cross-referenced different databases (ex. 
Hynet: yeast two-hybrid human protein-protein interaction database) to provide a 
stringent analysis of new hits (König et al. 2008). Zhou, et al. on the other hand, applied 
criteria for druggable targets (Hopkins and Groom 2002), narrowing 311 hits to 56 
candidates (Zhou et al. 2008). The overlap between the two genome-scale siRNA screens 
(Brass, et al. vs. Zhou, et al.) for HIV cofactors is greater than the amount of overlap that 
would be expected by chance (Zhou et al. 2008). This is an attractive direction for drug 
development, since antiviral medicines targeting host factors required for HIV infection 
or replication may provide a higher barrier to the development of resistance (Flexner 
2007). Currently, the NIH curates a database for these host factors in the NIH NIAID 
HIV-1 Human Protein Interaction Database found in this website: 
(http://www.ncbi.nlm.nih.gov/RefSeq/HIVInteractions/). 
One host factor discovered in siRNA screens from A. Brass, et al. is Transportin 3 
(TNPO3), a nuclear import protein that is required for HIV-1 infection (Brass et al. 
2008). Several independent groups have since explored the role for TNPO3 in nuclear 
import and maturation of the HIV-1 PIC (Diaz-Griffero 2012; Krishnan et al. 2010; Lee 
et al. 2010; Christ et al. 2008). 
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Another approach for identifying HIV-related host factors is to identify host 
proteins incorporated into HIV-1 virions (Ott 2008). This methodology, however, has 
some technical issues that need to be addressed. First, the protocol for purifying virions is 
of paramount importance, since contaminating proteins may cause spurious results (Bess 
et al. 1997; Gluschankof et al. 1997). Traditionally, virus may be purified from cell 
culture supernatants by ultracentrifugation through a sucrose cushion (Bess et al. 1992). 
An alternative or additional ultracentrifugation method is to use gradients of 60% w/v 
iodixanol (commercial name: OptiPrep), which allow the separation of cellular vesicles 
from virions. Another alternative method is CD45 immunodepletion of the supernatant, 
since HIV-1 virions do not have CD45 in their membranes while cellular vesicles do (Ott 
2008).  
After obtaining purified viral samples, the next step is the analysis of samples by 
mass spectrometry. However, failure to identify a protein by LC-MS/MS does not 
conclusively demonstrate that the protein is not present, since the absence of identifiable 
peptides can be due to several technical factors (Ott 2008). To confirm a candidate 
protein, detection by mass spectrometry must be complemented by functional data. 
E. Chertova and colleagues reported on host proteins isolated and identified by 
µRPLC-MS/MS from CCR5-tropic HIV-1 virions produced in monocyte-derived 
macrophages (Chertova et al. 2006). These virions were purified by density 
centrifugation and CD45 immunoaffinity depletion prior to µRPLC-MS/MS. Electron 
microscopy after CD45 depletion was performed to confirm purification of HIV-1 
virions.  
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A. Saphire and colleagues also reported a study on CXCR4-tropic HIV-1 virions 
produced from 293T cells and from Jurkat cells and purified through a sucrose cushion 
(Saphire et al. 2006). No significant difference was seen between identified proteins from 
the 293T set and from the Jurkat set. A. Saphire et al. identified previously known host 
factors incorporated into virions, such as cyclophilin A and Hsp70 (Saphire et al. 2006). 
They also identified proteins not previously known to be incorporated into HIV-1: 
histones and CD48 antigen (Saphire et al. 2006). 
D. Ott has proposed a classification of incorporated host proteins based on their 
functional significance to the virions (Ott 2002; 2008): 
 
1. Partners: ex. Staufen 1 
The overexpression of Staufen1 in virus-producing cells increases viral RNA and 
Staufen1 packaged in virions (Mouland et al. 2000). Interestingly, depletion of Staufen1 
in virus-producing cells also increases the amount of packaged viral RNA (Abrahamyan 
et al. 2010), possibly causing deregulation of assembly of newly synthesized virions. The 
current hypothesis is that Staufen1 assists in viral genome packing to produce fewer 
empty viral particles. The RNA may serve as a scaffold on which Gag organizes and 
assembles (Muriaux et al. 2001). 
 
2. Assassins: ex. APOBEC3G 
Since incorporation of this host factor potently inhibits HIV infectivity (reviewed in 
(Strebel et al. 2009)), this type of protein is actively excluded from virions. In this case, 
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the HIV-1 accessory protein Vif promotes the proteasomal degradation of cellular 
APOBEC3G, decreasing the amount available for encapsidation in nascent virions. 
APOBEC3G will be discussed further in Chapter III. 
 
3. Hostages/Captives: ex. Hsp70 
Heat shock protein 70 (Hsp70), a protein-folding chaperone, has transiently increased 
expression after HIV-1 infection (Wainberg et al. 1997). Incorporated Hsp70 associates 
with the mature viral core and is included at a 1:20 molar ratio relative to Gag (Gurer et 
al. 2002). It is postulated to play a role in maintaining the mature virion structure (Ott 
2008). 
 
4. Bystanders: ex. Tetraspanins 
A bystander protein is a host protein incorporated into nascent virions due to its 
proximity to the sites of viral budding on the plasma membrane. Its inclusion into virions, 
therefore, has no known function (Ott 2008). Tetraspanins, which are integral membrane 
proteins, are examples of this group. HIV-1 has been proposed to bud from tetraspanin-
enriched microdomains (TEMs), based on microscopy, cell fractionation data (Khurana et 
al. 2007; Nydegger et al. 2006) and the presence of tetraspanins in HIV-1 membranes 
(Ott 2002; Chertova et al. 2006). 
 
Cyclophilin A (CypA) was formerly classified as a captive. It has been shown to be 
required for optimal infectivity but not virus production (Thali et al. 1994; Franke et al. 
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1994). It is incorporated at 1:10 molar ratio with Gag (Ott 2002) and binds directly to CA 
(Luban et al. 1993). However it has since been shown that it is the CypA in 
target/infected cell, not the virion-associated CypA, which provides this function 
(Hatziioannou et al. 2005; Sokolskaja et al. 2004). It promotes DNA synthesis early after 
infection, perhaps by facilitating uncoating (Braaten et al. 1996; Sokolskaja et al. 2004). 
Since target cell-associated CypA functions in HIV-1 infectivity, virion-associated CypA 
has been proposed for re-classification as a bystander (Ott 2008). 
 
E. Host factors affecting HIV-1 
1. APOBEC3G: from the Old Guard of antivirals 
The HIV-1 virion infectivity factor (Vif) is required for viral replication in primary 
cells (CD4+ T cells) and some nonpermissive cell lines. This Vif requirement was 
presumably to overcome the presence of a restriction factor, since complementation 
assays using heterokaryon cell lines, which result from fusing a permissive cell line 
producing HIV-1 !Vif virions to a nonpermissive cell line, produced noninfectious 
virions (Madani and Kabat 1998; Simon et al. 1998). To identify this restriction factor, A. 
Sheehy and colleagues adopted a subtractive hybridization approach, gleaning a gene 
product present in a nonpermissive cell line but not expressed in permissive cell lines 
(Sheehy et al. 2002). Initially called CEM15 after the nomenclature of the nonpermissive 
cell line, it was later identified as APOBEC3G (apolipoprotein B mRNA-editing, 
enzyme-catalytic, polypeptide-like 3G), one of seven genes in a cluster on chromosome 
22 which code for cytidine deaminases (Jarmuz et al. 2002). These seven genes most 
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likely arose through gene duplication, as rodent APOBEC3 only has a single gene. All 
APOBEC3 proteins have either one or two copies of a cytidine deaminase zinc-
coordinating motif, which has histidine and cysteine residues, and a glutamic acid that 
serves as a proton shuttle (Jarmuz et al. 2002).  
 APOBEC3G most potently inhibits HIV-1, but APOBEC3F, APOBEC3B, and 
APOBEC3DE also have anti-HIV-1 activities (Bishop et al. 2006; 2004; Doehle et al. 
2005a; Holmes et al. 2007). APOBEC3G also suppresses Simian Immunodeficiency 
Virus (SIV) (Gaddis et al. 2004; Mangeat et al. 2003) and Murine Leukemia Virus 
(MLV) (Harris et al. 2003; Bishop et al. 2004; Doehle et al. 2005b). APOBEC3F and 
APOBEC3DE inhibit SIV (Yu et al. 2004a; Dang et al. 2006). APOBEC3B inhibits MLV  
(Doehle et al. 2005b) and HIV-1, and is also Vif-resistant (Doehle et al. 2005a). 
 Anti-Hepatitis B Virus (HBV) activity is also exhibited by APOBEC3G (Köck 
and Blum 2008; Noguchi et al. 2007), APOBEC3F (Bonvin et al. 2006; Rösler et al. 
2005), APOBEC3B (Bonvin et al. 2006), and APOBEC3C (Baumert et al. 2007; Köck 
and Blum 2008). APOBEC3A, a nuclear protein, inhibits adeno-associated Virus (AAV) 
(Chen et al. 2006) and HIV-1 in target macrophages and dendritic cells (Berger et al. 
2011). 
APOBEC3 proteins can also restrict mobile genetic elements (reviewed in (Chiu and 
Greene 2008)). This restriction is important for genome stability because 
retrotransposons can generate new copies of themselves through reverse transcription and 
re-insertion into the genome can potentially result in disease-causing mutations. 
APOBEC3C, APOBEC3F, and APOBEC3G can inhibit yeast Ty1 retrotransposons by 
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decreasing the number of transposed cDNAs and by extensive editing (Dutko et al. 2005; 
Schumacher et al. 2005). APOBEC3A, APOBEC3B, and APOBEC3G all inhibit mouse 
IAP and MusD elements (Esnault et al. 2005). It has been hypothesized that the 
expansion of the APOBEC3 locus evolved with the need to restrict and inactivate 
endogenous retroviruses and other mobile elements in the genome (Chiu and Greene 
2008). 
 
2. Tetherin: thwarting the viral escape 
HIV-1 accessory protein Viral protein u (Vpu) is required in certain nonpermissive 
cell lines to successfully release nascent virions; otherwise viral particles are retained on 
the cell surface, apparently tethered, and subsequently endocytosed (Neil et al. 2006; 
Varthakavi et al. 2003). This nonpermissive phenotype is interferon " (IFN")-inducible 
(Neil et al. 2007). To identify the restriction factor responsible, a microarray was 
performed and a candidate gene called BST-2/CD317, also dubbed “tetherin”, was 
identified. It is IFN"-inducible, recapitulated the Vpu-requiring phenotype and 
colocalized with Vpu (Neil et al. 2008) and Gag (Van Damme et al. 2008) on the cell 
surface.  
Tetherin is a type II single pass transmembrane protein with a transmembrane anchor 
on the N-terminus, an extracellular a helix, and a C-terminal glycophosphatidyl inositol 
(GPI) anchor (Kupzig et al. 2003). Disulfide bonds are formed between the three 
cysteines in the extracellular domain and the corresponding cysteines in the other tetherin 
monomer of the coiled-coil dimer (reviewed in (Malim and Bieniasz 2012)). The activity  
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Figure 1.4 Host factors affecting HIV-1 and other viruses. The host cell has evolved 
restrictions factors to limit the infection and propagation of unwanted invaders such as 
HIV-1. TRIM5" is postulated to be a pattern-recognition receptor that interacts and 
recognizes the incoming viral capsid. APOBEC3G is from the APOBEC3 family of 
cytidine deaminases that can restrict a wide-range of unwanted cellular parasites such as 
viruses and endogenous retrotransposons by mutating viral genomic material to render 
them noninfectious. Tetherin, a transmembrane protein, presents a final effort to restrict 
viral spread by preventing viruses from budding off the cell membrane. On the other 
hand, viruses have likewise developed mechanisms to co-opt host cellular functions, such 
as utilizing TSG101 and the ESCRT machinery to complete viral budding from the 
plasma membrane.  
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of tetherin seems to be fairly nonspecific, since a wide variety of viruses are restricted 
(Jouvenet et al. 2009). The mode of action of tetherin is thought to be simply cross-
linking the plasma membrane to the viral particles that have budded off. Tetherin 
tolerates mutations, including swapping whole domains with no detrimental effect 
(Perez-Caballero et al. 2009). Retroviruses which do not possess Vpu have evolved other 
tetherin antagonists (e.g. Nef protein for SIV) (Malim and Bieniasz 2012). 
 
3. TRIM5": intruder sensor alert 
TRIM5" was initially identified in a screen for rhesus macaques cellular factors that 
could restrict HIV-1 but were susceptible to SIV or MLV (Stremlau et al. 2004). 
Conversely, human TRIM5" can inhibit MLV but cannot restrict HIV-1 (Hatziioannou et 
al. 2004). Therefore, TRIM5" proteins are roadblocks to cross-species transmission since 
they cannot restrict retroviruses occurring in the same species but can effectively block 
other retroviruses.  
An independent report from Sayah et al. showed that owl monkeys are not susceptible 
to HIV-1 due to the presence of TRIMCyp, a fusion protein of TRIM5" with cyclophilin 
A replacing the SPRY domain, arising from a retrotransposon insertion (Sayah et al. 
2004). This restriction to HIV-1 is removed when the interaction of cyclophilin with the 
HIV-1 capsid is interrupted. 
The current model for the mechanism of action of TRIM5" is that it accelerates 
uncoating after viral entry, resulting in abortive reverse transcription (Malim and 
Bieniasz 2012). New data from T. Pertel et al. (Pertel et al. 2011) additionally show that 
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TRIM5" may be acting as a pattern recognition receptor (PRR) by its ability to identify 
the retroviral lattice of the capsid and to activate pathways of innate immunity. 
 
4. TSG101: a partner for cell break out 
Located on the C-terminal end of the Gag polyprotein is p6, which contains the late 
assembly domains (L domains), designated as such because they mediate the completion 
of viral budding from the plasma membrane (reviewed in (Weiss and Göttlinger 2011; 
Martin-Serrano and Neil 2011)). The importance of p6 was discovered when mutations 
on p6 resulted in the accumulation of budded viral particles still tethered to the plasma 
membrane of adherent cells, as visualized by transmission and scanning electron 
microscopy (Göttlinger et al. 1991). These p6 mutations also impaired proteolytic 
processing, with the accumulation of a Gag p25 intermediate (Göttlinger et al. 1991). The 
p6 domain contains a P(T/S)AP motif, which is highly conserved among primate 
lentiviruses (Strack et al. 2000) and constitutes the primary HIV-1 L domain required for 
budding (VerPlank et al. 2001). Other retroviruses have equivalent motifs that are 
required for virus release, and these different motifs are functionally interchangeable 
(Parent et al. 1995). These studies led to the hypothesis that L domains are docking sites 
for cellular factors necessary for virus release (Strack et al. 2000; Parent et al. 1995). 
Subsequently, several independent groups identified TSG101 (tumor suppressor gene 
101, also called Vps23) in yeast two-hybrid screens as specifically interacting with the 
PTAP motif of HIV-1 p6 (Martin-Serrano et al. 2001; Garrus et al. 2001; VerPlank et al. 
2001). PTAP-containing sequences in HIV-1 and the unrelated Ebola virus are required 
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for the recruitment of TSG101 (Martin-Serrano et al. 2001). Also, TSG101 recruitment is 
necessary for the formation of viral particles. TSG101 is a component of a 350-kDa 
complex, ESCRT-I (endosomal sorting complex required for transport–I), one of several 
ESCRT complexes tasked of packaging ubiquitinated cargo into multivesicular bodies for 
eventual degradation by lysosomes (Wollert and Hurley 2010). By utilizing TSG101, 
HIV-1 has the ability to co-opt the cellular machinery for forming vesicles, in this case 
facilitating the process of pinching off viral particles from the plasma membrane to 
release nascent virions.
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Chapter II 
Materials and Methods 
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A. APOBEC3G Study 
i. Cell culture and cell lines. Human embryonic kidney (HEK) 293 and H9 T cell 
lines were generous gifts from Dr. Eicke Latz and Dr. Mario Stevenson, 
respectively. HEK293, HEK 293T, and HeLa cell lines were maintained in 
DMEM (Invitrogen) supplemented with 10% FBS. H9 cells were maintained in 
RPMI (Invitrogen)-10% FBS media. All cell lines were grown at 37oC in a 
humidified incubator (5% CO2). Stable cell lines expressing A3G-YFP and point 
mutants were established by transfecting HEK293 and selecting for 12-14 days 
with 800 µg/mL G418 (Invitrogen) in DMEM-10% FBS following standard 
procedures. 
ii. Plasmids and transfections. Plasmids for expression of A3G-YFP and A3G-HA 
were previously described (Wichroski et al. 2006). Vectors for expressing 
APOBEC3G point mutants, except C100S and C291S, were constructed by site-
directed mutagenesis using PCR. Amplicons were inserted into the HindIII and 
Sac II sites of pEYFP-N1 (BD Biosciences). C100S and C291S were derived 
from plasmids pGST-APO3G C100S and C291S plasmids, which were 
generously provided by Dr. Judith Levine (Iwatani et al. 2006). The coding 
regions were amplified and modified to introduce restriction sites HindIII and 
SacII by PCR. Amplicons were inserted into pEYFP-N1 as above. All constructs 
were confirmed by sequencing. Single-cycle HIV-1 luciferase reporter proviral 
vectors pNL4-3.Luc.E-R- and pNL4-3.Luc.E-R- !Vif were generous gifts of Dr. 
Nathaniel Landau (Mariani et al. 2003). pLTR-VSV-G and full-length provirus 
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pLAI !Vif were kindly provided by Dr. Mario Stevenson. The HIV-1 
subgenomic vectors pNL-A1 and pNL-A1 !Vif were generous gifts of Dr. Klaus 
Strebel (Kao et al. 2003). Transfections were carried out using Lipofectamine 
2000 (Invitrogen) for HEK 293 and 293T following manufacturer’s instructions. 
HeLa was transfected using Lipofectamine (Invitrogen). Unless otherwise 
specified, transfections for virus production of pGIPZ (Open Biosystems, see 
below) lentiviral particle production were carried out using standard calcium 
phosphate procedure. 
iii. Virion production. Vectors coding for A3G-HA were co-transfected with pNL4-
3.Luc.E-R- !Vif and pLTR-VSV-G using Lipofectamine 2000. After 48 hours, 
supernatants containing virus were collected, clarified by low-speed 
centrifugation, and filtered (0.4 µm, Millipore). For packaging experiments, 
amounts of virions were quantified by p24 ELISA (Zeptometrix, Buffalo, NY) 
followed by ultracentrifugation of equal amounts of virions at 27000xg for 2 
hours at 4oC through a sucrose cushion. Antibodies "-p24 (Gag monoclonal #24-
4 from Dr. Michael Malim, NIAID, NIH), "-GFP (JL-8, Clontech) or "-HA 
(Santa Cruz Biotech) and "-APOBEC3G (affinity purified polyclonal rabbit 
antibody, Antibody Solutions, Palo Alto, CA; published in (Wichroski et al. 
2006)). For luciferase infectivity assays, target 293T cells were infected in 
triplicate with 10 ng of virus as determined by p24 ELISA. After 48 hours, total 
cell extracts were prepared from target cells and luciferase activity was measure 
after addition of Luciferase Substrate (Promega). 
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iv. Immunostaining and confocal microscopy. Preparation of samples for confocal 
microscopy was previously described (Wichroski et al. 2006; Chu and Rana 
2006). Primary antibodies "-DDX6/RCK (Bethyl) and "-myc (Santa Cruz 
Biotech) were used at 1:500 and 1:400, respectively. 
v. siRNA and shRNA knockdown. siRNAs (Dharmacon) targeting RCK, LSM1 
and GW182 were previously described (Chu and Rana 2006). 293T producer cells 
were transfected with 50 nM siRNA using Lipofectamine 2000. After 24 hours, 
cells were reseeded and transfected with a second dose of 50 nM siRNA plus 
proviral DNA pNL4-3.Luc.E-R- !Vif or subgenomic pNL-A1 !Vif (mock) and 
pLTR-VSV-G. Virions were prepared as above. siLSM1 nucleofection of H9 cells 
by Amaxa were performed following manufacturer’s recommendations. Knock 
down of LSM1 in H9 cells was accomplished using pGIPZ shRNA against LSM1 
(shLSM1, source ID V2LHS_213130, Open Biosystems). These lentiviral 
particles were produced by transfecting subconfluent 293T in a 100 mm dish with 
21 µg pGIPZ, 21 µg PAX2 (Gag-Pol, from AddGene), and 10.5 µg pMD2.G 
(VSV-G, from Addgene) using a standard calcium phosphate procedure. Virus 
supernatant was harvested after 48 hours, clarified by low speed centrifugation, 
filtered, and stored in aliquots at -80oC. Virus titers were determined according to 
manufacturer’s protocol. H9 cells were transduced at MOI=10 using spinoculation 
at 1200xg for 2 hours at room temperature with 8 µg/mL polybrene (Millipore). 
Fresh RPMI media was added the next day. Four days after transduction, H9 cells 
were treated with 0.5 µg/mL puromycin to select for transduced cells. After 2 
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days of selection, H9 was infected by spinoculation with 450 ng p24 equivalent of 
full-length LAI !Vif per 1x106 target cells. Three days after infection, virus 
supernatant was collected, clarified, and filtered. Virions were prepared and 
analyzed as above. 
vi. H9 infection and RNA extraction for miRNA microarray study. 293T cells in 
DMEM-10% FBS were transfected with pNL4-3 using Lipofectamine 2000. 
Supernatant was collected after 48 hours, cleared for cellular debris by a low-
speed spin, and passed through a 0.45 µM pore size filter (Millipore). Viral 
content was quantitated using p24 ELISA (Zeptometrix). Supernatant aliquots 
were stored in at -20oC.  The H9 infection protocol was adapted from published 
methods by D. Baltimore and colleagues and R. Gallo’s group (Kim et al. 1989; 
Popovic et al. 1984). Briefly, 1x107 H9 cells were washed and pre-treated with 10 
µg/mL polybrene (Chemicon) in RPMI-10% FBS at 37oC for 1 hour. Afterwards, 
the cells were again washed and split two-ways: one set (0.5x107 cells for 
infection) was resuspended in virus supernatant equivalent to 125 ng p24 and 
another set (0.5x107 cells for mock treatment) was resuspended in DMEM-10% 
FBS. Cells were incubated at 37oC, 5% CO2 for four hours, washed, and 
resuspended in RPMI-10% FBS. Infection was allowed to proceed for 5 passages 
and was monitored by p24 ELISA. H9 mock-treated and infected cells were 
collected after two weeks and washed with cold PBS. RNA was extracted using 
Trizol (Invitrogen), resuspended in nuclease-free water, and submitted to LC 
Sciences (Houston, TX) for miRNA profiling. 
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B. UPF1 Study 
i. Transfection of proviral constructs and over-expression vectors. All proviral 
constructs in this study are pNL4-3 env fs complemented with SR " NL4-3 env 
in trans. UPF1 was amplified from a pSPORT vector (accession number 
BC039817) and inserted into pcDNA3.1+, with an engineered HA tag in the N-
terminus of the protein (HA-UPF1). Vectors containing point mutations were 
constructed from this HA-UPF1. Transfections were carried out using standard 
calcium phosphate methods in T25 flasks using 2 µg proviral construct, 1 µg 
envelope, and 0.2 µg HA-UPF1. 
ii. siRNA experiments. Transfections for siRNA experiments were carried out in 
293T cells in 6-well format using standard Lipofectamine 2000 protocol. 10 nM 
siRNA against UPF1 were co-transfected with 0.76 µg proviral construct and 
0.38 µg envelope. Cells were washed 1 day after transfection and supernatant 
was collected 2 days after transfection for infectivity assays. 
iii. Assaying viral infectivity. Infectivity assays were performed in T25 flasks 
seeded previously with 50,000 GHOST CD4 CXCR4, which were infected with 
40 ng p24 equivalent supernatant as measured by ELISA. Infected cells were 
assayed for GFP expression 2 days p.i. by FACS. 
iv. Immunoblotting. Total cell lysates were resolved on SDS-PAGE and 
immunoblots were performed using the following antibodies: anti-HA from 
Covance, anti-HIV CA serum from NIH AIDS, anti-UPF1 (a generous gift from 
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Dr. Jens Lykke-Andersen; also from Bethyl), anti-gp120 (Fitzgerald Industries), 
anti-IN (IN-2) and anti-UPF2 (C-18) from Santa Cruz Biotech. 
v. Analysis of viral particles. Virions released in the medium from 293T cells 
transfected with pNL4-3 env fs were isolated as previously described (Popova et 
al. 2010). For UPF1 incorporation into virions, HA-UPF1 was co-transfected 
with proviral DNA. For determining nucleocapsid dependence, SVC vpu+ (with 
nucleocapsid) or SVC vpu+ GCN4p6 (without nucleocapsid) constructs were 
used. An additional spin using an OptiPrep gradient, as previously described 
(Dettenhofer and Yu 1999), was utilized to purify the virions away from 
microvesicles. 
vi. Analysis of virion-associated genomic RNA. After saving an aliquot for p24 
ELISA, virions produced from 293T were pelleted as above and viral RNA was 
recovered using the QiAMP Viral RNA kit (Qiagen). The viral RNA was then 
reverse transcribed using EcoDry strips (Clontech). The resulting cDNA was 
diluted 1:20 using TE/carrier DNA before use in Sybr Green-based assay using 
primers specific for full-length viral RNA(Buckman et al. 2003) . The raw signal 
was then normalized to the amount of p24 in the supernatant volume that was 
used for RNA extraction. 
vii. Analysis of viral fusion. The BLaM-Vpr protocol used for this study was 
modified from W. Greene and colleagues (Cavrois et al. 2002)and L. Brandano 
and M. Stevenson (Brandano and Stevenson 2012). Briefly, virus supernatant 
were produced from 293T transfected with 2 µg pNL4-3 env fs, 1 µg SR"NL4-3 
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env, 2 µg pMM310 (BLaM-Vpr construct), and 0.2 µg HA-UPF1 or mutant HA-
UPF1R865A. Virus supernatants were harvested, spun down, and filtered prior to 
addition to TZMbl cells plated previously at 30,000 cells per well in a 96-well 
plate. Infection was allowed to proceed for 2 hours at 37oC in a humidified 
incubator.  Afterwards, the supernatant was removed and dye solution 
(LiveBLAzer FRET-B/G CCF4-AM kit from Invitrogen) was added and the 
plate was incubated overnight at room temperature, protected from light. The 
next day, the dye solution was washed off and replaced by supplemented Hanks’ 
balanced salt solution (20 mM HEPES, 2 mM L-Glutamine). Blue cells were 
counted under a fluorescence microscope with Chroma filter set 41031 (Beta-
Lactamase, Blue/Aqua, EX HQ405/20X, BS 425DCXR, EM HQ430LP) for 5 
random fields, under 20x magnification and normalized to p24 content.  
viii. Analysis of post-entry events. Virus stocks were produced from 293T 
transfected with pNL4-3 env fs complemented with SR"NL4-3 env used and 
were treated with DNase prior to infection for early RT and late RT assays. 
GHOST CD4 CXCR4 target cells were infected in triplicate. The DNA from 
target cells was extracted 2 days p.i. using DNA Blood Mini Kit (Qiagen).  
Methods and primers previously described in Mbisa et al. (Mbisa et al. 2009) 
were used to prepare infected target cells for this assay.  The primer sets/probes 
used were: 1) Early RT: hRU5-F2, hRU5-R; 2) Late RT: MH531, MH532, LRT-
P; 3) 2-LTR circles: SS-4, LTR-R5, P-HUS-SS1. For the standard curves for 
early RT and late RT assays, 10-fold dilutions of linearized pNL4-3 plasmid 
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were used.  For the 2-LTR circle assay, the plasmid standard was kindly provided 
by Dr. Mark Sharkey (Sharkey et al. 2000).  DNA was normalized prior to 
quantitative PCR performed on a 7500 Fast Real-time PCR machine by Applied 
Biosystems using the standard format. Final values were obtained by subtracting 
corresponding “no env ctrl” (i.e. DNase-treated supernatants from samples not 
transfected with env expression vector) values. 
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Chapter III 
Disassembly of APOBEC3G ribonucleoprotein complexes 
in mRNA processing bodies does not affect APOBEC3G incorporation into HIV-1 
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A. Abstract  
APOBEC3G is a cytidine deaminase that inhibits HIV-1 lacking the virion 
infectivity factor (Vif). Newly-translated APOBEC3G are found in low-molecular mass 
(LMM) complexes and are subsequently recruited into high-molecular mass (HMM) 
ribonucleoprotein (RNP) complexes. Our group has previously shown that this 
APOBEC3G RNP is in processing bodies (P bodies), which are cytoplasmic foci of 
mRNA suppression and decay, but the role of this localization is unclear. To explore the 
functional relevance of APOBEC3G in P bodies, we constructed tagged APOBEC3G 
point mutations of amino acids in known motifs of the protein, including regions 
recognized to be essential for enzymatic activity, virion packaging, Vif sensitivity, and 
RNA binding. We then characterized their effect on expression level, subcellular 
localization, and packaging into virions. We found that none of the mutations abrogate P 
body localization. The importance of P body localization of APOBEC3G on virion 
packaging was also studied by disrupting P bodies through knockdown of P body 
components such as LSM1, RCK, and GW182. However, we did not see any significant 
changes in APOBEC3G viral packaging after the dispersal of P bodies. These findings 
suggest that APOBEC3G localized in P bodies do not constitute the pool of APOBEC3G 
that is recruited into HIV-1 virions; rather, APOBEC3G in P bodies may serve another 
purpose, such as to sequester and inactivate the enzyme in a subcellular component. 
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B. Background and rationale for study 
1. Discovery of APOBECs 
As discussed in Chapter I, APOBEC3G is a restriction factor against HIV-1 !Vif  
discovered in nonpermissive cell lines (Sheehy et al. 2002) but is downregulated by Vif 
(Marin et al. 2003; Sheehy et al. 2003). APOBEC3G belongs to a family of cytidine 
deaminases called APOBECs (apolipoprotein B mRNA editing enzyme catalytic 
polypeptide). They catalyze the hydrolytic deamination of the C4 position of the cytosine 
base (see Figure 3.1), converting cytidine to uridine. The cytidine deaminase motif is His-
Xaa-Glu-Xaa23-28-Pro-Cys-Xaa2-4-Cys, with a histidine and two cysteines coordinating a 
Zn++ ion and a glutamate residue for proton shuttling (Jarmuz et al. 2002). 
The first cytidine deaminase described in this family is APOBEC1, which was cloned 
in 1993 (Teng et al. 1993) and is expressed in small intestines to regulate cholesterol 
metabolism (Breslow 1988). Together with the APOBEC1 Complementation Factor 
(ACF), APOBEC1 edits ApoB100 mRNA (Navaratnam et al. 1995) by cytidine 
deamination (CAA!UAA corresponding to amino acid position 2153) (Johnson et al. 
1993; Navaratnam et al. 1993), introducing an in-frame stop codon to produce ApoB48, 
in contrast to full-length ApoB100 protein. Tight control of protein expression appears to 
be an important characteristic of this enzyme since editing becomes nonspecific when 
APOBEC1 is overexpressed in rat hepatomas cell lines (Sowden et al. 1996).  Transgenic 
rabbits and mice ectopically overexpressing APOBEC1 in liver tissue developed hepatic 
dysplasia and hepatocellular carcinoma (Qian et al. 1998). Another way of regulating 
APOBEC1 activity is by shifting its subcellular localization (Wedekind et al. 2003). 
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Figure 3.1 APOBEC3G deaminates cytosine at position C4, converting the base into 
uracil. 
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ApoB mRNA editing occurs in the cell nucleus. However, most of APOBEC-1 and ACF 
reside as inactive 60S complexes in the cytoplasm (Sowden et al. 2002; Yang et al. 
1997). This may be a mechanism for regulating the entry of editing complexes into the 
nucleus and preventing unwanted, nonspecific editing due to high levels of APOBEC1 
activity (Wedekind et al. 2003).  
Activation-induced cytidine deaminase (AID), another member of this family, 
mediates somatic hypermutation and class-switch recombination (Okazaki et al. 2002). 
Somatic hypermutation creates a population of B cells with increased affinity for a 
particular antigen by mutating the immunoglobulin variable region. On the other hand, 
class-switch recombination diversifies the immunoglobulin heavy-chain class: IgM, IgG, 
IgA, or IgE. These genetic modifications are essential for a normal immune response. 
However, overexpression of AID leads to lymphomas, probably due to increased amount 
of unrepaired DNA damage and translocations after AID-induced mutations (Lenz and 
Staudt 2010). AID functions as a DNA mutator (Petersen-Mahrt et al. 2002; Yoshikawa 
et al. 2002), in contrast to the RNA-editing APOBEC1 enzyme. 
 
2. Vif-mediated degradation of APOBEC3G 
The HIV accessory protein Vif mediates downregulation of APOBEC3G to prevent 
its incorporation into nascent virions. This Vif-mediated downregulation is accomplished 
via proteasome degradation of APOBEC3G. Vif recruits E3 ubiquitin ligase (cullinB-
ElonginB-ElonginC-Rbx complex) and induces poly-ubiquitination of APOBEC3G, 
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which targets APOBEC3G for proteasomal degradation (Marin et al. 2003; Sheehy et al. 
2003). 
A non-proteasome-mediated mechanism has also been postulated because Vif causes 
a 4.6-fold decrease in the synthesis of APOBEC3G protein, pointing towards 
transcriptional or translational modulation by Vif (Mariani et al. 2003). Additionally, Vif 
mutant S144A still induces APOBEC3G degradation (Mehle et al. 2004a) but does not 
fully rescue infectivity of virions (Yang and Gabuzda 1998). Vif depletes intracellular 
APOBEC3G by impairing translation of its mRNA (Kao et al. 2003; Mariani et al. 2003; 
Stopak et al. 2003) by binding to the 3’UTR and the 5’ UTR of APOBEC3G mRNA 
(Mercenne et al. 2010). 
 
3. Vif sensitivity of APOBEC3G 
A single amino acid at position 128 in APOBEC3G governs its sensitivity to HIV-1 
Vif (Bogerd et al. 2004; Mangeat et al. 2004; Mariani et al. 2003; Schröfelbauer et al. 
2004). When negatively charged D128 is mutated to positively charged K128, 
APOBEC3G gains resistance against HIV-1 Vif while becoming sensitive to Vif SIVagm. 
 
4. APOBEC3G structure 
APOBEC3G forms homo-multimers and is packaged as oligomers bound to RNA in 
virions. Multimerization is not required for its catalytic and antiviral activities (Opi et al. 
2006). The APOBEC3G C-terminal CD has five # strands flanked by an " helix on each 
side plus connecting loops (Chen et al. 2008; Holden et al. 2008; Zhang et al. 2007). 
55
5. Dissecting APOBEC3G antiviral activity 
Initially, APOBEC3G’s mode of action in the HIV-1 life cycle was ascribed to its 
ability to incorporate into nascent virions and subsequently hypermutate the viral cDNA 
during reverse transcription in newly-infected target cells (Mangeat et al. 2004; Zhang et 
al. 2003). The hypermutation results from deamination of cytidines into uridines during 
reverse transcription in the ssDNA minus strand, resulting in G ! A conversions in the 
plus strand. APOBEC3G deaminates cytidine in the context of the CC dinucleotide at 
multiple spots on the HIV-1 proviral DNA (Yu et al. 2004b; Suspène et al. 2006). Twin 
gradients of APOBEC3G editing with the maxima occur at the 5’ to the cPPT and the 
3’PPT (Suspène et al. 2006), which are the locations during reverse transcription where 
priming of the positive strand occurs (described in Chapter I). It is hypothesized that prior 
to this priming event, the single stranded minus strand at the cPPT and 3’ PPT are 
hotspots for the deaminase activity of APOBEC3G (Suspène et al. 2006). Only the C-
terminal cytidine deaminase (CD) domain is catalytically active, with the second domain 
functioning in nucleic acid binding and virus encapsidation (see Figure 3.4A). However, 
several studies show that APOBEC3G mutants lacking deaminase activity (i.e. alterations 
in the C-terminal CD motif) still demonstrate considerable residual antiviral effects 
(Bishop et al. 2006; Newman et al. 2005). Conversely, APOBEC3G-APOBEC3F 
chimeras retain deaminase activity but demonstrate diminished antiviral activity (Bishop 
et al. 2006). These findings suggest that deaminase-dependent hypermutation may not be 
a requirement for antiviral activity. One proposed mechanism for this deaminase-
independent antiviral activity is that APOBEC3G remains bound to viral genomic RNA, 
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preventing the viral reverse transcriptase from accessing its template (Soros et al. 2007). 
Since this deaminase-independent activity is an incomplete block, reverse transcription 
will occasionally occur, generating the minus-strand and providing the substrate for the 
deamination reaction. 
 
6. APOBEC3G complexes in the cell 
Several independent groups have demonstrated that APOBEC3G can be found in 
distinct complexes in the cell. Initially, APOBEC3G was reported to be in low-molecular 
mass (LMM) complexes and shift into high-molecular mass complexes (HMM) upon 
activation of CD4+ T cells (Chiu et al. 2005). Later, this paper was retracted (Chiu et al. 
2010) since the claim that APOBEC3G presents a post-entry restriction in inactivated 
cells was not repeatable (Kamata et al. 2009; Santoni de Sio and Trono 2009). However, 
subsequent work from W. Greene’s group have shown that APOBEC3G being found in 
LMM and HMM is reproducible (Chiu et al. 2006; 2010).  
At least two independent groups have demonstrated that newly translated 
APOBEC3G (“new A3G”) resides in these LMM complexes while “old A3G” assembles 
into HMM complexes (Goila-Gaur et al. 2009; Soros et al. 2007). This assembly has been 
shown to occur within 30-60 minutes after translation by pulse-chase assays. However, 
these reports have conflicting data as to which APOBEC3G is packaged into virions: V. 
Soros et al. reported that APOBEC3G in LMM are recruited into virions and become part 
of an intra-virion associated complex (Soros et al. 2007). However, R. Goila-Gaur et al. 
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demonstrated that APOBEC3G packaged into virions come from both the LMM and 
HMM populations (Goila-Gaur et al. 2009). 
These HMM A3G complexes are ribonucleoprotein assemblies, the identity of 
which have been variably described by several groups as either Staufen granules (Chiu et 
al. 2006), stress granules (Gallois-Montbrun et al. 2007; Kozak et al. 2006), polysome-
associated complexes (Kozak et al. 2006), or mRNA processing (P) bodies (our group 
(Wichroski et al. 2006) and (Gallois-Montbrun et al. 2007)). P bodies are punctate 
structures in the cytoplasm where mRNA degradation and mRNA translation repression 
occur (reviewed in (Eulalio et al. 2007)). In a related study, we have also shown evidence 
that implicates P body components in the suppression of HIV-1 (Nathans et al. 2009). 
We therefore want to explore the possibility that APOBEC3G located in P bodies 
may have a functional relevance to its antiviral effect against HIV-1. 
 
C. Hypothesis:  
APOBEC3G localization in processing bodies contributes to its antiviral function. 
 
D. Results 
1. APOBEC3G is a dynamic component of P bodies 
We first tested whether our current conditions for transfecting YFP-tagged 
APOBEC3G would yield an antiviral effect. We co-transfected luciferase-expressing 
proviral DNAs (+Vif or –Vif) with 15 fmol of APOBEC3G-YFP. We then assayed for 
infectivity of the resultant virus stocks by measuring for luciferase in infected 293T 
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Figure 3.2 APOBEC3G-YFP is antiviral. 293T cells were co-transfected with wild-type 
HIV-1 (+Vif) or !Vif (-Vif) luciferase-expressing proviral plasmid and APOBEC3-YFP. 
VSV-G-pseudotyped viral supernatants were normalized to particle number (p24) prior to 
infecting target cells and single cycle luciferase infectivity assay was measured 2 days 
after infection. 
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target cells after normalizing for p24 content. As expected, -Vif virus (!Vif Luc) 
produced in the presence of 15 fmol APOBEC3G-YFP has ~10-fold decreased infectivity 
compared to +Vif (i.e. wild-type) virus supernatant (Figure 3.2). These results 
demonstrate that exogenous, YFP-tagged APOBEC3G has potent antiviral activity 
against HIV-1 !Vif virus.  
APOBEC3G, together with Vif, localizes to mRNA processing bodies (P bodies)"
To test whether this subcellular localization is due to aggregates of APOBEC3G protein 
as opposed to functional APOBEC3G complexes, we utilized a diagnostic drug 
previously reported by N. Kedersha and P. Anderson that can differentiate dynamic P 
bodies versus transfection-induced protein aggregates in the cell (Kedersha and Anderson 
2007). They have shown that treatment of mammalian cells with emetine, a translation 
inhibitor, disperses P bodies, but not protein aggregates. To observe the effect of emetine 
in our system, we treated empty vector-transfected HEK293 cells with either 40 µg/mL 
emetine or DMSO (vehicle control) for 2 hours  and immunostained for RCK (a P body 
marker, (Cougot et al. 2004)). Empty vector-transfected cells lost their P bodies when 
treated with emetine, as seen by dispersal of RCK into the cytoplasm, while DMSO-
treated cells retained the RCK signal in punctate structures (Figure 3.3A).    
Next, we transiently transfected HEK293 cells with APOBEC3G-YFP (A3G-
YFP) and treated the cells with emetine. Similarly, A3G-YFP is also dispersed in 
emetine-treated HEK293, but not in DMSO-treated cells (Figure 3.3C). In addition, there 
is co-localization of A3G-YFP with RCK in DMSO-treated cells, indicating that in our 
current system, APOBEC3G is located in bona fide P bodies and is not forming protein  
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Figure 3.3 APOBEC3G is a dynamic component of processing bodies. (A) Emetine 
treatment (40 µg/mL, 2 hr incubation) disperses processing bodies in HEK293 cells, as 
seen by cytoplasmic redistribution of endogenous RCK (indirect immunostaining with 
RCK antibody), compared to DMSO vehicle control. Nuclei were stained with Hoechst 
33258 and images were merged digitally. (B) Emetine treatment does not affect protein 
levels of endogenous RCK or A3G-YFP. Total cell extracts from HEK293 cells 
transiently transfected with 0.5 µg empty vector or A3G-YFP were analyzed by 
immunoblot with antibodies against RCK or GFP. (C) Emetine treatment disperses 
processing body-localized A3G-YFP, resulting in diffuse cytoplasmic staining. A3G-YFP 
was detected by direct YFP fluorescence while RCK was detected as above. 
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aggregates. These results suggest that with our current overexpression conditions, 
APOBEC3G is a dynamic component of processing bodies that disperses into the 
cytoplasm when protein synthesis is halted. These results are also in agreement with 
previously published observations from our group using cycloheximide as a translation 
inhibitor (Wichroski et al. 2006). Our data suggests that APOBEC3G localization in P 
bodies is RNA-dependent, since emetine and cycloheximide inhibit translation elongation 
by stabilizing polysomes and blocking mRNA recruitment into P bodies (Kedersha et al. 
2005). Figure 3.3B shows that emetine treatment does not change total levels of RCK or 
A3G-YFP.   
 
2. Point mutations in APOBEC3G cytidine deaminase motif 1 and some 
residues on linker region 1 results in lower protein expression but still exhibit 
P body localization 
APOBEC3G contains two cytidine deaminase motifs (CD1, CD2, see Figure 
3.4A) and 2 linker regions (LR1, LR2). Both cytidine deaminase motifs contain the 
characteristic catalytic domain but only CD2 is enzymatically active. Mutations in the 
CD1 residues has been reported to decrease virion packaging and modestly affect protein 
stability (see Table 1) (Newman et al. 2005; Navarro et al. 2005) but antiviral and 
deaminase activities remain intact (Shindo et al. 2003; Navarro et al. 2005; Newman et 
al. 2005). As for CD2 mutant E259Q, the deaminase activity is removed (Newman et al. 
2005; Navarro et al. 2005) but reports on antiviral activity are conflicting. Studies with 
tagged recombinant proteins showed that E259Q partially lost its antiviral activity   
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Figure 3.4 Analysis of APOBEC3G point mutants. (A) Schematic diagram of 
APOBEC3G cytidine deaminase (CD) motifs and linker regions (LR), with 
corresponding functions and relevant residues. (B) YFP and HA-tagged point mutants of 
APOBEC3G were constructed for this study. Shown here are relative protein expression 
levels of tagged APOBEC3G mutants (HA-tagged: F70L, Y91A; YFP-tagged for the 
rest) compared to wild-type from total cell extracts of transiently transfected 293T cells. 
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(Shindo et al. 2003; Navarro et al. 2005); however, E. Newman et al., while working with 
untagged proteins, showed that E259Q still retains its antiviral activity, demonstrating 
that the deaminase activity is separate from its anti-HIV-1 properties (Newman et al. 
2005). The presence of the tag in recombinant proteins may therefore be interfering with 
the activity being measured (Newman et al. 2005). 
There are also conserved aromatic residues (F70, Y91 in CD1; F262, F282 in 
CD2) in both motifs, which were shown to be required for RNA binding in APOBEC1 
(Navaratnam et al. 1995).  
LR1 contains residues which determine Vif sensitivity and virion packaging 
(Huthoff and Malim 2007). D128 has been identified as the residue responsible for 
determining species-specific susceptibility to Vif (Janini et al. 2001; Mariani et al. 2003; 
Pace et al. 2006; Mangeat et al. 2004; Bogerd et al. 2004; Schröfelbauer et al. 2004). 
When D128 is mutated to lysine, it is incorporated into HIV-1 virions despite the 
presence of Vif. Other important residues in LR1 (see Table 1) include R122 (mutant 
defective in virion packaging while deaminase activity is intact; low-expressing), Y124 
(phenotype similar to R122, except expression level is like wild-type), W127 (leucine 
mutant is Vif-resistant), and P129 (mutant phenotype same as D128K). 
To determine whether P body localization is linked to any of the functional 
motifs, we mutated relevant residues to inactivate specific functions of the APOBEC3G 
protein (Figure 3.4A, in red). Figure 3.4B shows a comparison of the protein expression 
among these tagged mutants relative to wild-type protein. We observed that all mutations 
in CD1 and some in LR1 (specifically: H65R, E67Q, C97S, C100S, F70L, Y91A, 
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R122A, and W127L) resulted in lower protein expression, suggesting that these residues 
contribute to protein stability (Figure 3.4B).  
To confirm this, we determined the mRNA abundance of representative low-
expressing mutants (E67Q, W127L) and compared them to the mRNA levels of wild-
type APOBEC3G and high-expressing mutants Y124A and E259Q by quantitative PCR. 
As expected, the mRNA levels of the low-expressing mutants were similar to wild-type 
and high-expressing mutants (Figure 3.5A). 
To take a snapshot of newly-synthesized low-expressing mutant proteins, we 
performed metabolic labeling on tagged E67Q. Synchronized 293T cells previously 
transfected with either wild-type APOBEC3G (A3G-HA) or mutant E67Q (E67Q-HA) 
were pulsed with S35-labeled methionine. Cell lysates were then collected at several time-
points up to 30 minutes (APOBEC3G t1/2 ~29 min, (Mehle et al. 2004b)) during the pulse 
process, followed by immunoprecipitation with an HA antibody. In Figure 3.5B, we show 
that the amount of newly-synthesized, radiolabeled mutant E67Q lags behind wild-type 
APOBEC3G, suggesting that the mutation in the glutamate of CD1 might be altering the 
stability of the newly-synthesized mutant protein in our current system. 
We then asked if the low-expressing mutants are being turned over quickly by the 
proteasome. We addressed this, utilizing ALLN, a proteasome inhibitor, to determine 
whether we can rescue the low-expressing mutant proteins. Cells transiently transfected 
with representative low-expressing and high-expressing mutants were treated with 100 
µM ALLN overnight prior to harvesting. As a positive control for protein recovery, wild-
type A3G-YFP was co-transfected with or without Vif expression vector and similarly  
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Figure 3.5 Mutations in CD1 and some LR1 residues decreases APOBEC3G protein 
stability. (A) Relative mRNA and protein levels of representative APOBEC3G mutants 
compared to wild-type APOBEC3G, normalized to GAPDH and neomycin (vector 
internal control) mRNA levels (B) Synchronized 293T cells transiently transfected with 
either wild-type A3G-HA or E67Q-HA were pulsed with S35-methionine and collected at 
indicated time points followed by IP with "-HA (C) Proteasome inhibition with ALLN 
partially recovers protein levels of low-expressing APOBEC3G mutants E67Q and 
C100S. Wild-type A3G-YFP recovery in the presence of Vif was used as positive control 
for ALLN.  
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treated with 100 µM ALLN. Total cell lysates analyzed by immunoblotting (Figure 3.5C, 
left panel) showed diminished wild-type A3G-YFP when co-expressed with Vif, but with 
recovery to near normal levels (i.e. without Vif) upon treatment with ALLN. There is 
also the appearance of bands migrating faster than full-length protein, which are 
presumably polyubiquitinated products. APOBEC3G low expressing mutants also show 
some recovery of protein levels with proteasome inhibition (Figure 3.5C, right panel) but 
are still not on par with the high-expressing mutant Y124A. These results indicate that 
the low protein expression of CD1 mutants and some LR1 mutants is partially due to 
faster turnover of the mutant proteins. 
To characterize P body localization even under conditions of low protein 
expression, we propagated HEK293 cells stably expressing representative YFP-tagged 
mutant proteins with G418 as a selection marker. Confocal microscopy was performed 
using indirect immunofluorescence against endogenous RCK and direct 
immunofluorescence for APOBEC3G protein localization. As seen in Figure 3.6, most of 
the signal of wild-type A3G-YFP co-localizes with RCK in P bodies, while the rest of the 
signal was diffused in the cytoplasm. Representative CD2 mutants C291S-YFP and 
E259Q-YFP displayed a pattern of localization similar to wild-type protein. Mutants 
C100S and E67Q, which have mutations in CD1 on the corresponding residues, showed 
lower signal intensity on confocal microscopy, reflecting lower protein expression. 
However, some signal can still be clearly seen to colocalize with RCK in P bodies. 
D128K also showed wild-type subcellular localization. Y124A, which is not encapsidated  
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Figure 3.6 Confocal study of P body localization for APOBEC3G mutants. HEK293 
stable cell lines expressing representative YFP-tagged APOBEC3G mutants demonstrate 
decreased over-all signal for low-expressing mutants E67Q and C100S but localization to 
processing bodies is still observed.  
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in virions, also displayed wild-type localization. Our results suggest that localization to P 
bodies does not correlate to packaging of APOBEC3G in virions. 
 
3. P body depletion does not affect virion packaging of endogenous or 
exogenous APOBEC3G 
APOBEC3G requires encapsidation in newly-assembled !Vif virions to restrict 
the next round of infection. We therefore wanted to test whether we can perturb 
APOBEC3G viral packaging by disruption of processing bodies in virus-producing cells. 
To examine this, we depleted LSM1, another P body protein (Cougot et al. 2004), in H9 
cells by Amaxa nucleofection, as H9 cells are not amenable to siRNA transfection with 
Lipofectamine 2000. We then infected these H9 cells with fully-replicating !Vif virus. 
To check whether LSM1 was depleted in H9 cells, we assayed LSM1 mRNA levels by 
quantitative PCR and LSM1 protein levels by immunoblotting. Transfection of H9 cells 
with either 300 nM or 1 µM siRNA depleted LSM1, as seen in Figure 3.7A. We decided 
to use 300 nM for subsequent experiments since using the lowest needed concentration of 
siRNA would minimize any off target effects. 
H9 cells depleted of LSM1 were infected with !Vif and the virus supernatants 
were collected four days post-infection (p.i.).  Virions were purified from the 
supernatants and normalized for particle production. Viral lysates were then analyzed by 
immunoblotting for APOBEC3G and p24. We saw no significant difference in 
APOBEC3G content of virions produced after LSM1 depletion compared to si_Ctrl-
treated samples (Figure 3.7B). LSM1 knockdown in H9 cells was confirmed by qPCR  
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Figure 3.7 Depletion of LSM1 by siRNA nucleofection in H9 !Vif virus-producing 
cells does not affect endogenous APOBEC3G encapsidation into virions. (A) 
Optimization of siRNA conditions in nucleofected H9 cells shows depletion of LSM1, as 
assayed by qPCR and immunoblotting. (B) Purified virions produced from LSM1-
depleted H9 cells are assayed by immunoblotting for virion-associated endogenous 
APOBEC3G. (C) Depletion of LSM1 in virus-producing H9 cells was assayed by qPCR. 
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(Figure 3.7C). These results suggest that disruption of processing bodies by LSM1 
depletion does not affect packaging of endogenous APOBEC3G in !Vif virions. 
However, it is possible that we do not see an effect since LSM1 depletion is not efficient 
using this method. Additionally, we observed that Amaxa nucleofection resulted in 
increased cytotoxicity for H9 cells, as seen by Trypan blue exclusion (Appendix 3.4). 
Therefore, we sought another method to deplete LSM1.  
We tested several clones from the pGIPZ library targeting LSM1 (shLSM1) and 
found that shLSM1_343 resulted in the most efficient knockdown of our target protein 
(Figure 3.8A). We also compared spinoculation, wherein high speed centrifugation is 
performed during incubation with the shRNA supernatant (O'Doherty et al. 2000), as a 
method of transducing H9 cells, in contrast to incubation only. With our current 
conditions, we found no difference between the two methods (Figure 3.8C). While 
optimizing for MOI (multiplicity of infection) and puromycin selection conditions, we 
observed that increasing MOI resulted in increased GFP signal (i.e. transduction 
efficiency) but also increased cytotoxicity, as seen with Trypan Blue exclusion. This is 
probably due to the increased amount of VSV-G in the virus supernatant, which was used 
to pseudotype the shRNA viral-like particles (VLPs). We therefore used the lowest MOI 
(MOI=10) that results in successful transduction for subsequent experiments. 
In brief, we produced shRNA virus-like particles (VLPs) in 293T cells and 
transduced H9 cells by spinoculation. After two days of selection with puromycin, we 
then infected the H9 cells with !Vif virions and collected virus supernatant four days p.i. 
Virions were purified and analyzed as above. In Figure 3.8C, left panel, we show that  
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Figure 3.8 Depletion of LSM1 by shRNA transduction in H9 !Vif virus-producing 
cells does not affect endogenous APOBEC3G encapsidation into virions. (A) 
Optimization of shRNA conditions in transduced H9 cells shows depletion of LSM1, as 
assayed by qPCR and immunoblotting. (B) Transduction methods (spinoculation vs. 
incubation) and MOI conditions were compared for efficiency of transduction, as 
measured by immunoblotting for LSM1 and GAPDH (loading control). (C) LSM1 
depletion in H9 cells were assayed by immunoblotting (total cell lysates, left panel). 
Purified virions produced from LSM1-depleted H9 cells were assayed for virion-
associated endogenous APOBEC3G by immunoblotting. (D) Depletion of LSM1 in H9 
cells results in disruption of P bodies, as seen in confocal microscopy. 
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LSM1 is depleted in H9 total cell lysates. Also, endogenous APOBEC3G encapsidation 
in !Vif virions is unaffected despite LSM1 depletion (Figure 3.8C, right panel). In 
parallel, we confirmed P body disruption upon shLSM1 transduction in H9 using indirect 
immunostaining for RCK (Figure 3.8D, lower right panel).  
Concurrently, we also investigated the effect of depleting other P body proteins 
on the packaging of exogenous A3G-HA into !Vif virions. Figure 3.9A (lanes 1-3) 
shows the efficient knockdown of GW182, another P body marker (Cougot et al. 2004), 
using siRNA in 293T total cell lysates. The !Vif virion lysates showed no difference in 
the packaging of A3G-HA upon depletion of GW182 (lane 7) compared to si_Ctrl (lane 
10) for 293T cells transfected with 1 µg A3G-HA expression vector. Unexpectedly, when 
2 µg A3G-HA expression vector is transfected, there is no A3G-HA packaged in both 
si_GW132 and si_Ctrl !Vif virions. Figure 3.9B shows the disruption of P bodies upon 
GW182 depletion using indirect immunofluorescence in 293T cells. 
We also repeated these experiments using siRNA against RCK and saw similar 
results (Figures 3.9C, lane 7 vs. lane 10). As a negative control for virion encapsidation, 
we utilized APOBEC3G Y124A, which is excluded from virions. As expected, Y124A 
mutant was not detected in the virion lysates (Figure 3.9C, lane 8 and lane 11). 
Taken together, our results demonstrate that P bodies can be disrupted by 
depleting a P body resident protein (LSM1, GW182, or RCK) but dispersing P bodies 
does not affect encapsidation of exogenous or endogenous APOBEC3G. This suggests 
that the APOBEC3G fraction in P bodies is not the source of APOBEC3G included in 
nascent virions, since manipulating this P body fraction does not affect virion packaging  
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Figure 3.9 Dispersion of P bodies in virus-producing cells does not affect viral 
encapsidation of exogenous APOBEC3G. (A) 293T cells were co-transfected with 
indicated siRNAs, proviral DNA, and APOBEC3G-HA plasmid. Total cell lysates were 
immunoblotted for GW182 depletion and expression of A3G-HA and p24. Purified 
virions were assayed for virion-associated A3G-HA. (B) Depletion of GW182 disperses 
P bodies in 293T cells, as seen using indirect immunofluorescence for RCK staining. (C) 
293T cells were co-transfected with indicated siRNAs, proviral DNA, and APOBEC3G-
HA wild-type or Y124A mutant. Total cell lysates were immunoblotted for RCK 
depletion and expression of A3G-HA and p24. Purified virions were assayed for virion-
associated A3G-HA.  
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of APOBEC3G. Our results agree with V. Soros et al. (Soros et al. 2007) because they 
demonstrated that APOBEC3G which associates with virions is from the newly-
synthesized APOBEC3G found in the LMM A3G fraction and not the HMM A3G 
complexes. In contrast, R. Goila-Gaur et al. (Goila-Gaur et al. 2009) have reported that 
new A3G in LMM and old A3G in HMM are packaged in virions at similar efficiencies. 
 
4. Vif inhibitor RN-18 increases total APOBEC3G protein levels that localize to 
P bodies. 
The Vif inhibitor RN-18 was identified by our group in a small molecule library 
screen as an enhancer of APOBEC3G expression in the presence of Vif through a 
pathway independent of general proteasome inhibition (Nathans et al. 2008). We were 
curious, therefore, whether RN-18 would affect APOBEC3G localization in processing 
bodies. In Figure 3.10A (left panels), A3G-YFP is expressed with or without Vif 
expression vector, demonstrating baseline APOBEC3G localization and expression level 
in P bodies in the presence and absence of Vif. As expected, co-expression of Vif 
obliterates APOBEC3G signal both in P bodies and in the cytoplasm (Figure 3.10A, left 
lowermost panel). K. Stopak and colleagues have previously shown that co-expression of 
Vif with APOBEC3G shortens its half-life (Stopak et al. 2003). However, cells treated 
with increasing amounts of RN-18 display increased APOBEC3G signal in the P body 
compartment above the baseline signal (Figure 3.10A, right panels) and accompanied by 
increased number of P bodies, suggesting that total APOBEC3G expression in the cells 
may be increased by the drug. To confirm this, we analyzed total cell lysates by    
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Figure 3.10 RN-18 enhances APOBEC3G protein expression. (A) HeLa cells were co-
transfected with APOBEC3G-YFP, with or without a Vif-expressing construct, and were 
treated with either DMSO or increasing concentrations of inhibitor RN-18. Cells were 
then fixed and analyzed using confocal microscopy. (B) Total cell lysates were analyzed 
for A3G-YFP and Vif protein levels with immunoblotting.  
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immunoblotting. Figure 3.10B demonstrates increasing amounts of A3G-YFP protein 
levels upon RN-18 treatment in a dose-dependent manner, despite the presence of Vif. 
With the highest RN-18 dose (50 µM), A3G-YFP protein levels are even higher (Figure 
3.10B, lane 4) than A3G-YFP expressed without Vif (Figure 3.10B, lane 5). These data 
are in agreement with previously published observations from our group, which showed 
APOBEC3G protein stabilization in the presence of Vif upon RN-18 treatment (Nathans 
et al. 2008). Taken together, these results indicate that RN-18 increases the total 
APOBEC3G levels in the cells, resulting in increased APOBEC3G content of different 
subcellular compartments, including the APOBEC3G fraction in P bodies. This increase 
in total APOBEC3G also explains why there is increased APOBEC3G packaged in 
virions when treated with RN-18. 
 
E. Discussion  
1. APOBEC3G and AIDS progression 
Hypermutation in clinical samples of HIV-1 proviruses has previously been 
reported, showing an over-representation of G!A substitutions (Janini et al. 2001; Pace 
et al. 2006). However, there are conflicting reports as to whether these G!A 
hypermutations are APOBEC3-mediated (specifically, APOBEC3G and APOBEC3F) 
and whether they contribute toward slowing progression to AIDS. K. Gandhi et al. 
(Gandhi et al. 2008) showed that there is no correlation between A3G expression and 
hypermutation rate or disease state when long-term nonprogressors (LTNP) were 
compared to non-controllers (NC) on HAART. On the other hand, Y. Kourteva and 
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colleagues (Kourteva et al. 2012) have found a strong inverse correlation between HIV-1 
plasma RNA and A3G-mediated hypermutation after stratifying subject samples by their 
“Hypermutation Index”, which corrects for length of sequences and RT error rate. Also, 
they have brought up the issue of using unselected, HAART-naïve patients since some of 
them might turn out to be spontaneous controllers. Careful dichotomy of patient subjects 
(LNTP vs. NC on HAART) and larger study populations have been recommended.  
While APOBEC3G’s contribution to the clinical progression (or non-progression) 
of HIV-1/AIDS is still unclear, it nevertheless clearly acts as a restriction factor with 
several modes of action. It is of interest to study APOBEC3G biology to elucidate the 
pathways involved and to continue efforts in developing therapeutic targets related to it 
(e.g. Vif inhibitors). Also, measuring hypermutation as a footprint of APOBEC3G’s 
activity may underestimate the antiviral activity since hypermutation and antiviral 
activities are separable. The amount of reverse transcripts in infected cells appear to be a 
stronger correlate for antiviral activity (Holmes et al. 2007; Mbisa et al. 2007). 
 
2. An independent study of APOBEC3G and P bodies 
During the preparation of this manuscript, R. D’Aquila and colleagues published 
a report detailing how A3G complexes affect HIV-1 virus production (Martin et al. 
2011). Similar to our work, they analyzed several tagged APOBEC3G mutants (C97A, 
Y124A, W127L, and D128K) with respect to subcellular localization. They report that 
the C97A mutant has a predominantly nuclear localization at 24 hours but this reverts to 
wild-type APOBEC3G localization at 48 hours, which they describe as mostly diffuse 
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cytoplasmic signal and with punctate structures that partially co-localize with RNA 
granules (RCK, GW182) and late endosomes (CD63). We did not see this phenotype 
with our C97S mutant, although our time frame for analysis is ~18–24 hr post-
transfection. Also, we transfect 0.5 µg plasmid or less while they transfected 2 µg 
expression vector. In their hands, treatment with a translation inhibitor (cycloheximide) 
had no effect on the A3G complexes, while our use of emetine disperses the punctate 
structures (Figure 3.3C). However, they checked the expression level of exogenous 
APOBEC3G and found that it is similar to endogenous APOBEC3G in CEM cells and 
activated CD4+ T cells. It is therefore difficult to conclude whether the phenotype they 
see with the C97A mutant is due to protein aggregates or not. Alternatively, it is possible 
that the alanine mutant of C97 has a different phenotype compared to the serine mutant.  
R. D’Aquila and colleagues also report that !Vif HIV-1 production is decreased 
in the presence of A3G complexes while RCK depletion, which disperses the A3G 
complexes, results in increased HIV-1 production. This is similar to what we previously 
observed (Appendix 3.5, (Nathans et al. 2009)). However, they do not see any increase in 
virus production for wild-type (Vif+) HIV-1. 
 
3. Small molecules enhance APOBEC3G protein expression 
Our group has previously described the effect of Vif inhibitor RN18 on 
APOBEC3G levels: RN18 rescues APOBEC3G protein levels in a Vif-dependent manner 
(Nathans et al. 2008). In this study, RN-18 increases APOBEC3G levels beyond baseline 
levels (i.e. without Vif, Figure 3.10B), with increased signal in P body-associated 
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APOBEC3G by confocal microscopy (Figure 3.10A). It is possible that Vif may be 
recruiting APOBEC3G into HMM/PB complexes (Goila-Gaur et al. 2009). Alternatively, 
RN-18 may be increasing the total amount of APOBEC3G in all the subpopulations in 
the cell, either by stabilizing APOBEC3G in complex with Vif or by increasing 
APOBEC3G translation. As a result, more APOBEC3G is packaged into virions, 
resulting in less infectious virus despite the presence of Vif (Nathans et al. 2008). 
An independent group has reported another anti-HIV drug called SN-2, that also 
increases APOBEC3G levels above baseline despite the presence of Vif (Ejima et al. 
2011). The authors demonstrated an increase in APOBEC3G protein levels assayed by 
western blot after drug treatment (Ejima et al. 2011). Both SN-2 and RN18 have similar 
scaffolds. It would be interesting to find out if confocal data using SN-2 would be similar 
to our results, as these two drugs may have similar mechanisms in counter-acting Vif. 
 
4. Proposed model for APOBEC3G compartments in the cell 
Our data support a model (Figure 3.11) wherein APOBEC3G distributes into 
several compartments in the cell. Newly-translated APOBEC3G is found in LMM A3G 
complexes and these are recruited into HMM A3G complexes such as P bodies. 
Activation of cells results in a shift from LMM A3G complexes into HMM A3G 
complexes. This would explain why APOBEC3G in P bodies is seen more clearly in 
activated CD4+ T cells compared to unstimulated cells (see Appendix 3.5). Interestingly, 
Rose et al. (Rose et al. 2004) have reported that activating cells with phorbol myristate 
acetate results in increased transcription and translation of APOBEC3G in H9 cells. The  
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Figure 3.11 Proposed model for APOBEC3G compartments in the cell. Newly-
synthesized APOBEC3G proteins are found in low-molecular mass (LMM) complexes, 
which are localized diffusely throughout the cytoplasm. APOBEC3G that associates with 
assembling virions presumably come from this population. Within 30 minutes, these 
APOBEC3G proteins are recruited into high-molecular mass (HMM) ribonucleoprotein 
(RNP) complexes, which may be processing bodies, stress granules, and/or polysome-
associated RNP complexes, possibly to sequester and inactivate the APOBEC3G 
deaminase. RNase-treatment converts these HMM RNP complexes into LMM 
complexes, with APOBEC3G recovering its deaminase activity. On the other hand, 
depletion of P body components apparently disrupts these HMM RNP, as seen by its 
dispersal in confocal microscopy, but these dispersed HMM RNP complexes may still be 
distinct from the LMM complexes, since encapsidation of APOBEC3G into virions is 
unaffected. Overexpression of APOBEC3G or stabilization of APOBEC3G protein (ex. 
with RN-18) results in increased total APOBEC3G levels, including APOBEC3G found 
in P bodies. 
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shift into HMM may therefore be a reflection of increased total amounts of APOBEC3G, 
either by upregulating transcription and translation or by adding a drug like RN-18, 
which may slow down the turn-over of the protein. Also, similar to APOBEC1 
(Wedekind et al. 2003), moving APOBEC3G to HMM complexes may possibly be a 
mechanism to sequester and inactivate APOBEC3G. The HMM can be converted to 
LMM by RNase treatment, which restores deaminase activity (Chiu et al. 2005). The 
HMM may also be disassembled by utilizing translation inhibitors (emetine, 
cycloheximide) or by depleting P body proteins, although loss of the structural P bodies 
does not seem to shift the HMM A3G into the LMM fraction, since APOBEC3G 
packaging is not affected. It is possible that the HMM A3G complexes are simply 
dispersed in the cytoplasm but are still in sub-microscopic ribonucleoprotein complexes 
that are distinct from the LMM fraction. Further experiments need to done to address this 
possibility. 
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Appendix for Chapter III 
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Appendix 3.1 Endogenous APOBEC3G expression and localization in resting and 
activated primary CD4+ T cells. Resting primary CD4+T cells show relative low 
APOBEC3G expression, with less than 10% of cells showing punctate spots that co-
localize with LSM1 (P body marker). Upon activation, the APOBEC3G signal is 
increased, with almost all cells demonstrating LSM1-co-localizing spots. Primary CD4+ 
T cells were obtained from peripheral blood mononuclear cells. Cells were treated with 
Cell-Tak to promote adherence to cover slips and were fixed with 4% paraformaldehyde, 
followed by permeabilization prior to immunolabeling with LSM1 and APOBEC3G 
antibodies. 
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Appendix 3.2 APOBEC3G expression and subcellular localization in transiently 
transfected 293T cells. (A) To determine whether mutations in known APOBEC3G 
motifs disrupt its localization to P bodies, HeLa cells were transiently transfected with 
YFP-tagged APOBEC3G constructs. At 1 day post-transfection (p.t.), cells were fixed 
and analyzed by direct immunofluorescence microscopy. (B) 293T cells were transiently 
transfected with YFP-tagged APOBEC3G with mutations in residues important for RNA 
binding and analyzed by confocal microscopy after immunostaining for RCK at 1 day p.t. 
(C) 293T cells were transiently transfected with YFP-tagged APOBEC3G LR1 mutants 
(except D128K) and analyzed as in above. 
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Appendix 3.3 P body protein DCP2 interacts with APOBEC3G wild-type and 
mutant proteins. To determine whether APOBEC3G mutations abrogate interactions 
with P body components, 293T cells were co-transfected with YFP-DCP2 (a P body 
protein) and representative HA-tagged APOBEC3G constructs. Total cell lysates were 
immunoprecipitated with "-HA and analyzed by immunoblotting.  
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Appendix 3.4 H9 cell viability after Amaxa nucleofection. To determine whether 
Amaxa nucleofection conditions were cytotoxic, H9 cells were counted using the Trypan 
Blue exclusion method. 
105
106
Appendix 3.5 Effect of depletion of P body components on HIV-1 production and 
single cycle infectivity. (A) To determine whether P bodies play a role in the HIV-1 life 
cycle, RCK (a P body marker) was depleted by siRNA transfection in either !Vif virus-
producing (KD Producer) or virus-infected (KD Target) 293T cells and assayed for single 
cycle infectivity, as seen in the right panels. Target cells were transfected by siRNA one 
day prior to infection. Virus production of wild-type and !Vif-producing 293T cells were 
also measured by 24 ELISA after depletion of RCK in virus-producing cells, as seen in 
the left panels. RCK depletion was assayed by immunoblotting cell lysates for RCK and 
GAPDH (loading control). (B) AGO2, another P body protein, was likewise depleted in 
293T cells which were subsequently infected with either wild-type or !Vif virions 
pseudotyped with VSV-G and single cycle infectivity was measured. (C) Total cell 
lysates for a time-course experiment in RCK-depleted virus-producing 293T cells were 
immunoblotted for RCK, p24, and GAPDH (loading control). 
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Appendix 3.6 Effect of miR29a on HIV-1. (A) RNA samples from mock and HIV-
infected H9 cells were prepared and submitted for miRNA profiling. During analysis of 
the microarray data, miR29a was found to target the HIV-1 3’UTR (3’LTR) and is highly 
expressed in H9 cells, with increased levels upon HIV-1 infection. (B) To determine 
whether miR29a modulates HIV-1, we utilized 2’-O-methyl oligonucleotides 
complementary to miR29a to inhibit miR29a (20 nM miR29a Inhibitor) in virus-
producing cells and assayed for virus production (p24 ELISA) and single cycle 
infectivity.
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Appendix 3.7 Effect of miR138 on APOBEC3G protein levels. (A) H9 cells, which 
express APOBEC3G, have undetectable levels of miR138. On the other hand, 293T and 
HeLa cells, which do not express endogenous APOBEC3G, have measurable levels of 
miR138. (B) Target sequence of miR138 on APOBEC3G 3’UTR (A3G-3’UTR, 
numbering corresponds to 3’UTR only) and on cloned reporter construct pGL3-A3G-
3’UTR. (C) To determine whether miR138 affects APOBEC3G protein levels, a dual 
luciferase assay was performed with reporter construct pGL3-A3G-3’UTR after 
transfection of 20 nM miR138 inhibitor. 
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Cellular host factor UPF1 is required  
in an early, post-entry step of the HIV-1 life cycle 
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A. Abstract 
The putative RNA helicase MOV10 is packaged into HIV-1 virions and inhibits 
their infectivity at the level of reverse transcription. UPF1 (also known as RENT1) is a 
ubiquitously expressed helicase related to MOV10 with well-documented roles in 
regulating nonsense-mediated decay in organisms from yeast to mammals. We have 
observed that UPF1, like MOV10, is packaged into HIV-1 virions in a nucleocapsid-
dependent manner. Unlike MOV10, UPF1 did not inhibit the infectivity of progeny 
virions when overexpressed. However, the depletion of UPF1 or the overexpression of 
UPF1 mutants defective for ATP binding, ATP hydrolysis, or RNA binding in virus-
producing cells significantly decreased the single-cycle infectivity of HIV-1 virions. In 
contrast, MOV10 was ineffectual in restricting HIV-1 when mutated to prevent ATP 
hydrolysis. To determine which step in the HIV-1 life cycle requires UPF1, we utilized a 
dominant-negative UPF1 mutant and assayed different steps of the life cycle. The 
dominant-negative UPF1 mutant did not affect HIV-1 Gag processing or the 
incorporation of Gag-Pol, Env, or of viral genomic RNA into virions. The same 
nonfunctional mutant did not affect the integrity of encapsidated genomic viral RNA or 
viral entry into target cells. However, virions produced in the presence of the dominant 
negative UPF1 mutant yielded decreased amounts of early and late reverse transcriptase 
products and of 2-LTR circles in infected cells. Taken together, our findings reveal an 
important role for UPF1 during the early phase of the HIV-1 life cycle. 
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B. Background and rationale for study 
MOV10 was initially identified as a host protein incorporated in HIV-1 virions 
produced by monocyte-derived macrophages (Chertova et al. 2006). More recently, 
several independent groups have described MOV10 as an antiviral host protein that, 
when overexpressed in virus-producing cells, restricts the infectivity of virions in the 
target cells (Arjan-Odedra et al. 2012; Burdick et al. 2010; Furtak et al. 2010; Wang et al. 
2010). However, depletion of endogenous MOV10 does not affect viral production or 
infectivity (Arjan-Odedra et al. 2012). Although the mechanism of its antiviral action is 
still unclear, it has been shown to decrease early reverse transcription and nuclear 
transport of the proviral DNA (Arjan-Odedra et al. 2012; Burdick et al. 2010; Furtak et 
al. 2010; Wang et al. 2010).  
MOV10 is the human homolog of the Mov10 protein from the synonymously 
named mouse strain infected with the Moloney murine leukemia virus (Jaenisch et al. 
1981; Mooslehner et al. 1991). Human MOV10 has been documented to localize in 
processing bodies (P bodies) (Meister et al. 2005; Gallois-Montbrun et al. 2007). An 
earlier report by T. Tuschl and colleagues showed that MOV10 is required for miR21-
guided mRNA cleavage (Meister et al. 2005). However, recent work by M. Malim and 
colleagues demonstrated that MOV10 is not necessary for endogenous let7 miRNA-
mediated mRNA repression in HeLa cells (Arjan-Odedra et al. 2012).  
MOV10, like APOBEC3G, also restricts mobile genetic elements.  MOV10 
inhibits transposition of human endogenous retrotransposons LINE-1 and Alu, and also 
of mouse endogenous retrovirus IAP (Arjan-Odedra et al. 2012). Armitage, the MOV10 
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ortholog in Drosophila, has likewise been shown to curb endogenous mobile elements 
(Olivieri et al. 2010; Tomari et al. 2004). 
MOV10 and UPF1, a MOV10-related protein, were identified concurrently by 
protein sequencing in our lab as host proteins incorporated in HIV-1 virions produced in 
293T cells (H. Göttlinger, unpublished observations). Interestingly, both UPF1 and 
MOV10 belong to the same subfamily of SF1 helicases: SF1-B" (B directionality is 
5’!3’ while type " translocation occurs on a single-stranded substrate; also designated 
as Upf1-like helicases (Fairman-Williams et al. 2010; Koonin 1992; Singleton et al. 
2007)). Both have the characteristic 7 helicase motifs in the C-terminal half of the 
protein. However, a helicase function for MOV10 has not yet been reported. The 
stoichiometry of both in purified virions is currently not known.  
A. Mouland et al. have also documented UPF1 as a host protein that is packaged 
into HIV-1 virions (Abrahamyan et al. 2010). Preliminary data from their group 
suggested that UPF1 stabilizes Gag mRNA in the cytoplasm of virus-producing cells 
(Ajamian et al. 2008). Increased UPF1 incorporation into virions was seen when Staufen1 
(Stau1), a UPF1-interacting protein, is depleted in virus-producing cells. Notably, Stau1 
depletion causes decreased viral infectivity and an increased amount of packaged viral 
genomic RNA (Abrahamyan et al. 2010). Overexpression of Stau1 in virus-producing 
cells also increases viral RNA and Stau1 packaged into virions (Mouland et al. 2000). A. 
Mouland and colleagues have proposed that Stau1 plays a role in viral assembly, 
especially in the packaging of exactly two copies of the genomic RNA (Abrahamyan et 
al. 2010), since more or less than two copies would result in decreased viral infectivity. 
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UPF1 (for up-frameshift 1; also known as RENT1, regulator of nonsense 
transcripts 1) was initially discovered in a genetic screen in yeast (Upf1, also called 
NAM7 in S. cerevisiae) (Leeds et al. 1992). Homologs have been described in D. 
melanogaster (Upf1), C. elegans (SMG2), and mammals (reviewed in (Nicholson et al. 
2009)). UPF1 is an ATP-requiring 5’! 3’ helicase and unwinds both RNA and DNA in 
vitro (Bhattacharya et al. 2000; Czaplinski et al. 1995). In these experiments, UPF1 forms 
complexes with both kinds of nucleic acids in the absence of ATP and requires its 
ATPase activity to release the bound nucleic acid (Czaplinski et al. 1995; Weng et al. 
1998). More recent work demonstrated that UPF1’s ATPase activity is dependent on 
RNA (Chamieh et al. 2008), with ATP binding and hydrolysis inducing a conformational 
change in the UPF1 helicase domain, probably altering its RNA binding capacity (Cheng 
et al. 2007). In general, RNA-dependent ATPases can clamp onto the RNA and unwind 
nucleic acids, hence the term “helicase” (Chakrabarti et al. 2011). Alternatively, helicases 
can function as translocases, displacing proteins associated to an RNA substrate 
(Jankowsky et al. 2001). 
UPF1 has a well-characterized role in the nonsense-mediated decay (NMD) 
pathway (see Figure 4.1A, also (Czaplinski et al. 1995), reviewed in (Amrani et al. 2006; 
Brogna and Wen 2009; Isken and Maquat 2008; Singh and Lykke-Andersen 2003)), 
which maintains error-free RNA in the cell and regulates genomic noise (Mendell et al. 
2004). UPF1, UPF2, and UPF3 (isoforms UPF3a and UPF3b in mammalian cells) are the 
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Figure 4.1 UPF1 is a multifunctional protein. (A) UPF1 is one of the core proteins, 
together with UPF2 and UPF3a/b, of the nonsense-mediated decay (NMD) pathway. (B) 
UPF1 is recruited by Staufen1 (Stau1) and interacts with eukaryotic release factors in the 
Staufen-mediated decay (SMD) pathway. (C) Schematic diagram of the UPF1 protein 
showing the CH domain (binding site for UPF2 and Stau1), the helicase domain, and 
S/T/Q residues for phosphorylation. 
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highly-conserved, core proteins in a surveillance complex for this NMD pathway (He et 
al. 1997; Serin et al. 2001). The stoichiometry of yeast Upf1, Upf2, and Upf3 per cell has 
been estimated  as follows: ~1,600 molecules of Upf1, ~160 molecules of Upf2, ~ 80 
molecules of Upf3 (Maderazo et al. 2000). As for localization within the cell, the 
following quantitation of immunofluorescent signal in the nucleus was performed in 
HeLa cells: UPF1 ~14%, UPF2 ~25%, UPF3 ~46% (Iborra et al. 2004), suggesting that 
UPF1 and UPF2 are mostly in the cytoplasm. 
When translation termination factors eukaryotic release factor 1 (eRF1) and eRF3 
encounter a stalled ribosome due to a premature stop codon (PTC), they recruit UPF1, 
which links the surveillance machinery to translation termination events (Czaplinski et al. 
1998; Ivanov et al. 2008; Kashima et al. 2006). UPF1 bound to eRF1 and eRF3 is 
phosphorylated by SMG1, and this allows UPF2 binding. UPF2 is an activator of UPF1 
(Chakrabarti et al. 2011), since UPF2 bound to UPF1 alters UPF1 conformation, resulting 
in less RNA binding (Chamieh et al. 2008). Unphosphorylated UPF1 interacts with 
SMG1 and eRF3, while phospho-UPF1 interacts with mRNA decay factors (Isken and 
Maquat 2008). The NMD pathway is further regulated by the phosphorylation and 
dephosphorylation cycle of UPF1, the latter step catalyzed by protein phosphatase 2A 
(PP2A) (Ohnishi et al. 2003).  
In human cells, UPF2 and UPF3b stably interact and are required for 
phosphorylation of UPF1. Both are components of the exon-junction complex (EJC) 
(Baker and Parker 2004; Chamieh et al. 2008; Maquat 2004), which is deposited by the 
spliceosome 20-24 nt upstream of a splice site after an intron is removed, and recruit 
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UPF1 to this complex (Buchwald et al. 2010; Chamieh et al. 2008; Gehring et al. 2003; 
Kashima et al. 2006). The EJC, although not essential for mammalian NMD (Bühler et al. 
2006), is postulated to be a modulator of this pathway (Amrani et al. 2006). The EJC 
provides a platform for interaction of the NMD core machinery (Le Hir et al. 2001), 
improves the translatability of transcripts, since translation and NMD are closely linked, 
and helps distinguish a nonsense stop codon from a normal stop codon. The proposed 
EJC model postulates that a PTC is recognized when an EJC complex is situated 50-55 nt 
downstream of a stop codon (Kashima et al. 2006; Le Hir et al. 2001; 2000; Maquat 
2004; Shibuya et al. 2004; Sun and Maquat 2000; Tange et al. 2004). On the other hand, 
recognition of a PTC in the yeast NMD pathway has been described using the proposed 
faux 3"UTR model, wherein the stop codon is deemed abnormal because it occurs a long 
distance from the 3" end, preventing the normal interaction between the terminating 
ribosome and the poly(A) binding protein (PABP) (Amrani et al. 2004). Instead, NMD 
factors associate with the terminating ribosome (Amrani et al. 2006; Brogna and Wen 
2009). But UPF1’s ability to sense the length of the 3’UTR is not limited to yeast cells. A 
study by J. Hogg and S. Goff showed UPF1-dependent sensing and degradation of 
mRNAs with long 3’UTRs (Hogg and Goff 2010). UPF1 increasingly associates with 
mRNAs containing longer 3’UTRs, especially transcripts that are NMD-sensitive (Hogg 
and Goff 2010). The commitment to undergo decay was found to occur independently 
from the UPF1-dependent sensing step (Hogg and Goff 2010). Also, insertion of 
retroviral sequences that promote translational read-through of stop codons decreased 
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UPF1 association with mRNAs, stabilizing the transcripts and uncoupling the sensing 
step from the initiation of decay (Hogg and Goff 2010). 
After the NMD machinery identifies a stop codon as premature or aberrant, the 
NMD substrate is degraded by  the mRNA turnover pathway (via decapping and/or 
deadenylation of the mRNA) or through endonucleolytic cleavage (Mühlemann and 
Lykke-Andersen 2010). NMD factors and substrates have been observed in P bodies 
(Durand et al. 2007; Sheth and Parker 2006), but there is no direct evidence that 
localization in these structures is a prerequisite for degradation. In fact, several groups 
failed to observe defects in both translation and mRNA turnover under conditions where 
formation of microscopically detectable P bodies was prevented (Eulalio et al. 2007; 
Stoecklin et al. 2006; Rehwinkel et al. 2005). NMD factors and substrates are only 
strongly observed in P bodies when the late steps in the NMD pathway are inhibited, such 
as inhibiting UPF1 ATPase activity or UPF1 dephosphorylation (Durand et al. 2007; 
Stoecklin et al. 2006; Stalder and Mühlemann 2009). 
The UPF1 ATPase activity is essential for NMD (Bhattacharya et al. 2000; 
Czaplinski et al. 1995; Sun et al. 1998). The UPF1 mutant K498A, which lacks ATP 
binding and ATPase activity, has no NMD function (Chamieh et al. 2008). J. Lykke-
Andersen and colleagues utilized this mutant to demonstrate that the ATPase-dependent 
function of UPF1 is also required in the disassembly of the NMD ribonucleoprotein 
complex after the mRNA undergoes degradation; otherwise, NMD factors accumulate in 
P bodies (Franks et al. 2010).  
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UPF1 is also engaged in the Staufen-mediated decay (SMD) pathway (see Figure 
4.1B). Stau1 binds to a hairpin loop on the 3’UTR of some mRNAs and recruits UPF1 for 
the eventual degradation of these transcripts (Isken and Maquat 2008). SMD can be 
distinguished from NMD because it is EJC-independent (Kim et al. 2005; Meyer and 
Gavis 2005). Substrates described for SMD include PAX3 mRNA (Gong et al. 2009) and 
ADP-ribosylation factor 1 (Arf1) mRNA (Kim et al. 2005; 2007).  
The CH motif of the UPF1 protein (see Figure 4.1C) serves as the binding site for 
UPF2 (Kadlec et al. 2006) and Stau1 (Gong et al. 2009), with mutually exclusive binding 
(see Figure 4.1C). Upon binding to UPF2, the CH domain adopts a conformation such 
that UPF1 switches from RNA clamping to RNA unwinding activity (Chakrabarti et al. 
2011). Biochemical characterization of the UPF complex by H. Le Hir and colleagues 
also showed that addition of UPF2 decreases RNA binding and increases ATPase and 
ATP-dependent unwinding activity of UPF1. Since UPF2 mainly interfaces with the CH 
domain, this suggests that UPF2 binding to the CH domain activates the UPF1 helicase 
function (Chamieh et al. 2008). A cryo-EM study of the UPF1-UPF2-UPF3 complex 
suggests that UPF2 interaction sequesters the UPF1 CH domain, allowing the helicase 
region to remain accessible (Melero et al. 2012). The inhibitory effect of the CH domain 
is intramolecular, since the addition of 10-fold excess CH domain to UPF1 !CH has no 
effect (Chamieh et al. 2008).  
Aside from NMD and SMD substrates, UPF1 is also involved in the degradation 
of a third class of mRNA. H. Kaygun and W. Marzluff have demonstrated that histone 
mRNA requires UPF1 for its regulated degradation upon DNA inhibition and exit from S 
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phase (Kaygun and Marzluff 2005). Histone mRNAs are remarkable such that they are 
not polyadenylated at the 3’ end but rather possess a conserved stem loop structure 
(Dominski and Marzluff 1999). The stem loop binding protein (SBLP) binds to this RNA 
structure (Dominski et al. 1999) and recruits UPF1 (Kaygun and Marzluff 2005). This 
pathway is UPF2-independent but still requires UPF1’s ATPase activity (Kaygun and 
Marzluff 2005). In the same study, ataxia telangiectasia and Rad3 related (ATR), a key 
regulator of the DNA damage checkpoint pathway, was also found to be required for 
histone mRNA degradation (Kaygun and Marzluff 2005). Presumably, ATR may be 
phosphorylating either UPF1 or SBLP to trigger the cascade of events leading to histone 
mRNA degradation. SMG1 requirement for UPF1 phosphorylation was not addressed in 
this study. 
A fourth class of RNA is also impacted by UPF1. Telomere-repeat containing 
RNA (TERRA) is a noncoding RNA transcribed from telomeres (Azzalin et al. 2007; 
Schoeftner and Blasco 2008), which are DNA sequences found at the end of chromatin 
that progressively shorten with each cell division until they reach a critical length that 
signals the cells to undergo senescence. C. Azzalin and colleagues found that TERRA is 
negatively regulated by UPF1 and SMG1: depletion of UPF1 or SMG1 results in 
accumulation of TERRA at telomeres, although the half-life and total cellular levels of 
TERRA were unaffected (Azzalin et al. 2007). Also, depletion of UPF1 resulted in the 
loss of telomeric tracts (Azzalin et al. 2007). UPF2 seems to contribute minimally to this 
pathway (Azzalin et al. 2007). These preliminary findings suggest that UPF1 may play a 
role in displacing TERRA from telomeres. A newer study from R. Chawla  et al. 
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demonstrated using chromatin immunoprecipitation experiments that a fraction of UPF1 
is recruited in telomeres during S and G2/M phases in an ATR-dependent manner 
(Chawla et al. 2011). UPF1’s ATPase function is needed for telomere stability, 
particularly in leading strand replication (Chawla et al. 2011). C. Azzalin and colleagues 
hypothesize that UPF1 helps maintain genomic stability by facilitating telomere 
replication and telomere length (Chawla et al. 2011).  
A preliminary study by V. Narry Kim’s group suggests a possible role for UPF1 
in miRNA-mediated mRNA downregulation (Jin et al. 2009). UPF1 binds to RNA-
induced silencing complex (RISC) proteins AGO1 and AGO2 (Jin et al. 2009). Also, 
UPF1 depletion decreases the binding of Hmga2 mRNA, a target of let-7 miRNA, onto 
RISC (Jin et al. 2009). In parallel experiments, overexpression of a UPF1 mutant lacking 
helicase activity increases the amount of bound Hmga2 mRNA to RISC (Jin et al. 2009), 
suggesting that UPF1 may play a role in the degradation of the miRNA target as well. V. 
Narry Kim’s group have therefore proposed that, based on their data, UPF1 participates 
in RNA silencing by facilitating the binding of RISC to the target and by accelerating the 
decay of the mRNA (Jin et al. 2009). 
UPF1 also plays an essential role in the cell, which is not necessarily NMD-
related. UPF1 knockout mice do not survive beyond peri-implantation stage (3.5 days 
post-coitum) (Medghalchi et al. 2001). This is consistent with findings by C. Azzalin and 
J. Lingner, wherein UPF1-depleted cell lines underwent S phase arrest after one week, 
leading to a hypothesis that UPF1 may be playing a role during DNA replication and 
repair (Azzalin and Lingner 2006a). Another observation supporting this hypothesis is 
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that UPF1 physically interacts with the processive lagging strand DNA pol $ and the 
DNA dependent RNA polymerase II machinery (Carastro et al. 2002; Iborra et al. 2004; 
Azzalin and Lingner 2006a). 
Like UPF1, UPF2 is required in embryonic development since UPF2 null 
embryos were lost by day 9.5 (Weischenfeldt et al. 2008). On the other hand, UPF2 
conditional knockout mice have different phenotypes, depending on the tissue involved. 
Liver-specific UPF2 knockout in fetal mice leads to perinatal death (Thoren et al. 2010). 
Similarly, loss of UPF2 in adult livers of mice led to extensive liver damage (Thoren et 
al. 2010). However, UPF2 conditional knockout in the hematopoetic system of mice 
showed that differentiated cells, but not progenitor cells, tolerate UPF2 loss 
(Weischenfeldt et al. 2008).  
UPF1 is a phosphoprotein, with three known kinases: SMG1, ATM, and ATR 
(Azzalin and Lingner 2006b; Brumbaugh et al. 2004; Yamashita et al.).  Having different 
kinases might be a mechanism to regulate UPF1’s varied roles in several pathways 
(Azzalin and Lingner 2006a). Phosphorylation sites on UPF1 are found in S/T and Q 
residues in the C-terminal end of the protein (see Figure 4.1C).  
Given that UPF1 is an essential, multifunctional protein involved in several 
cellular pathways, we therefore sought to determine whether UPF1 is also required by 
HIV-1 in its viral life cycle. In this study, we observed that depletion of endogenous 
UPF1 or overexpression of nonfunctional UPF1 mutants in virus-producing cells 
decreases single-cycle infectivity. To characterize this UPF1 requirement by the virus, we 
assayed the effect of a dominant negative mutant on viral proteins and on the 
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incorporation of the viral genomic RNA into virions and found that these were 
unaffected. Lastly, we also measured the effect of the dominant negative mutant on the 
early steps of the life cycle, namely, viral entry, reverse transcription, and nuclear import. 
We found that viral entry is unaffected but reverse transcripts, and 2-LTR circles were 
decreased by the UPF1 dominant negative mutant. Our results, taken together, 
demonstrate that UPF1 is a host protein that plays an important role in an early stage of 
the HIV-1 life cycle. 
 
C. Hypothesis:  
UPF1 is a host factor that may be required for HIV-1 infectivity. 
 
D. Results 
1. HIV-1 virions incorporate UPF1 and MOV10 in a nucleocapsid-dependent 
manner.  
We have identified UPF1, together with related protein MOV10, as a host protein 
packaged in HIV-1 virions by protein microsequencing (H. Göttlinger, unpublished data).  
To demonstrate incorporation of MOV10 into virions, we transfected 293T with HA-
tagged MOV10 (HA-MOV10) together with wild-type proviral DNA (WT). The virions 
were purified through a sucrose cushion, and the virion lysates were resolved on an SDS-
PAGE gel. As seen in Figure 4.2A (left lane), HA-MOV10 is detected in WT virions.  
The viral nucleocapsid (NC) acts as the chaperone protein responsible for packaging 
the viral genome and other components of the viral core. To determine whether MOV10  
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Figure 4.2 HIV-1 virions encapsidate MOV10 and UPF1 in a nucleocapsid-
dependent manner. (A) 293T cells were transfected with either WT HIV-1 or HIV-1 
lacking nucleocapsid (No NC) constructs plus HA-MOV10. Total cell lysates and 
purified virions were analyzed by Western blotting. (B) 293T cells were transfected with 
negative control (None) or WT HIV-1 construct (WT), together with HA-UPF1. Cell 
lysates and purified virions were analyzed with anti-CA serum for Gag and anti-HA 
antibody. (C) 293T cells were transfected with either WT HIV-1 or HIV-1 lacking 
nucleocapsid (No NC) constructs, and HA-UPF1. Total cell lysates and purified virions 
were analyzed by Western blotting as above.  
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requires the viral NC for incorporation into virions, we transfected a proviral construct 
with NC replaced by a leucine zipper (No NC) (Accola et al. 2000). Virion-like particles 
(VLPs) obtained from this sample did not contain detectable HA-MOV10 (Figure 4.2A, 
right lane), which suggests that MOV10 is dependent on NC for virion packaging.  This 
corroborates the findings of Wang et al., wherein they show that MOV10 interacts with 
NC in an RNA-dependent manner using a GST pull-down experiment (Wang et al. 
2010).  
To confirm UPF1 incorporation into virions, we isolated virions produced in 293T 
cells co-transfected with HA-tagged UPF1 (HA-UPF1). Since the majority of UPF1 is in 
a complex with ribosomes (Atkin et al. 1995), which may co-sediment with virions 
through a sucrose cushion, we performed a second ultracentrifugation step utilizing an 
OptiPrep (60% iodixanol solution) step gradient to purify virions away from 
microvesicles (Dettenhofer and Yu 1999). After the sequential ultracentrifugation, we 
immunoblotted virion lysates for Gag and HA. Figure 4.2B shows the Gag and the HA 
signals for the wild-type virions and none for the negative control, indicating that UPF1 
is specifically packaged into HIV-1 virions. To determine whether UPF1 requires the 
viral NC for incorporation into virions, we transfected 293T cells with the same proviral 
construct lacking NC used above. In Figure 4.2C, we show that HA-UPF1 is not 
incorporated into VLPs lacking NC (No NC), suggesting that UPF1 is packaged into 
virions in a NC-dependent manner. Therefore, both MOV10 and UPF1 are incorporated 
into HIV-1 virions through interactions with NC. However, it is unclear at this point if 
UPF1 interacts with the NC directly or in complex with RNA. 
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2. MOV10 and UPF1 have opposite effects on single-cycle HIV-1 infectivity.  
To begin studying the effects of MOV10 and UPF1 on HIV-1 infectivity, we utilized 
a single cycle infectivity assay in which we provide viral Env in trans to obtain single-
cycle virions and measure infectivity in GHOST CD4 CXCR4 cells. This reporter cell 
line expresses GFP under viral LTR control, with GFP+ signaling a successful infection. 
We co-transfected either HA-MOV10 or  HA-UPF1 with the proviral constructs in 293T 
virus-producing cells. We then infected GHOST CD4 CXCR4 cells with equivalent 
amounts of virus as measured by p24. In Figure 4.3B, we show that MOV10 profoundly 
inhibits the single-cycle infectivity of HIV-1 when overexpressed in virus-producing 
cells, which is in agreement with previously published data by several groups (Arjan-
Odedra et al. 2012; Burdick et al. 2010; Furtak et al. 2010; Wang et al. 2010). On the 
other hand, we saw that overexpression of UPF1 in virus-producing cells produced 
virions whose infectivity did not differ significantly from that of virions produced in the 
presence of an empty vector (Figure 4.3A). To further study the effect of MOV10 and 
UPF1 on HIV-1 infectivity, we constructed ATPase-deficient mutants for each helicase. 
In this case, MOV10DE645AA overexpression in virus-producing cells lost its restrictive 
effect (Figure 4.3C) while UPF1DE636AA overexpression decreased the infectivity of HIV-
1 virions by ~20-fold (Figure 4.3A). This suggests that ATPase-deficient UPF1 has a 
dominant negative effect on the single-cycle infectivity of HIV-1. In contrast, MOV10’s 
inhibition of HIV-1 infectivity is dependent on its ATPase activity. 
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Figure 4.3 Opposite effects of overexpression of UPF1 and MOV10 wild-type 
protein and ATPase mutants on HIV-1 single cycle infectivity. (A) 293T cells 
were transfected with proviral constructs to produce single cycle virions and co-
transfected with empty vector, HA-UPF1, or corresponding ATPase mutant HA-
UPF1DE636AA. Virus supernatant equivalent to indicated inoculum were used to 
infect GHOST CD4 CXCR4 indicator cells. Infected cells were harvested and 
analyzed by FACS for LTR-driven GFP expression at 2 days p.i. (B) Virus 
supernatants were prepared as above, this time co-transfected with HA-MOV10. 
(C) Virus supernatants were prepared as above, co-transfected with either empty 
vector or MOV10 ATPase mutant HA-MOV10DE645AA. 
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3. Point mutations in UPF1 catalytic domain motifs cause dominant negative 
effects on HIV-1 single cycle infectivity. 
To further assess the role of the helicase domain of UPF1 in the HIV-1 life cycle, we 
constructed additional point mutations in HA-UPF1 to inactivate specific functions of the 
UPF1 catalytic domain (Bhattacharya et al. 2000; Cheng et al. 2007; Czaplinski et al. 
1995; Weng et al. 1996; Chen et al. 2012): HA-UPF1DE636AA and HA-UPF1Q665A, which 
both lose ATPase activity (Cheng et al. 2007); HA-UPF1R703A and HA-UPF1K498A, which 
both lose ATP binding and ATPase activity (Cheng et al. 2007; Czaplinski et al. 1995); 
and HA-UPF1R865A, which prevents P body accumulation in the yeast homolog (Cheng et 
al. 2007), suggesting loss of RNA binding, in addition to loss of ATP binding and 
ATPase activities (summary in Table 4.1). These mutants were overexpressed 
individually in virus-producing 293T cells (Figure 4.4A), and single-cycle virions 
equivalent to 40 ng p24 were assayed for infectivity in GHOST CD4 CXCR4 cells. All 
mutant proteins were expressed at similar levels (Figure 4.4A). Figure 4.4B shows that 
overexpression of almost all mutants in virus-producing cells decreases single cycle virus 
infectivity, compared to wild-type HA-UPF1 or empty vector. In independent 
experiments by E. Popova from our lab, the HA-UPF1DE636AA mutant decreased 
infectivity by as much as 20-fold (Figure 4.3A). In my experiments, the HA-UPF1R865A 
mutant causes the greatest decrease in infectivity (~10-fold, Figure 4.4B). HA-UPF1Q665A 
only had a mild effect (decreased by ~1.3-fold). Residue Q665, an uncharged amino acid, 
has only a minor effect when mutated to alanine, suggesting the importance of the other 
charged residues in maintaining the UPF1 function we are investigating. These results   
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Figure 4.4 Overexpression of UPF1 catalytic domain mutants decreases HIV-1 single 
cycle infectivity. (A) Total cell lysates of 293T transiently transfected with 2 µg pNL4-3 
env-, 1 µg SR"NL4-3 env, and 0.2 µg HA-UPF1 or mutant and immunoblotted with anti-
HA and anti-actin antibody demonstrates relative protein expression of UPF1 catalytic 
domain mutants. (B) FACS analysis for single-cycle infectivity assay performed on 
GHOST CD4 CXCR4 2 days p.i. with single-cycle virions produced in the presence of 
overexpressed UPF1 constructs. 
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demonstrate that UPF1 catalytic domain mutants have a dominant negative effect on 
HIV-1 single cycle infectivity. 
 
4. HIV-1 single cycle infectivity involves endogenous UPF1 but not UPF2.  
To determine whether UPF1 is required by HIV-1, we depleted endogenous UPF1 via 
the transient transfection of siRNA into virus-producing 293T cells (Figure 4.5A, left 
panel) and assayed for the single-cycle infectivities of the virions. When assaying for 
infectivity, we performed infections of GHOST CD4 CXCR4 indicator cells, which 
express GFP upon infection with HIV-1. The cells were infected using equivalent 
amounts of virus as measured by p24 and examined for GFP expression using FACS 
(Figure 4.5B). Here, we clearly see that HIV-1 single cycle infectivity is reduced to 
almost background levels upon knockdown of endogenous UPF1 in virus-producing 
cells.  
In parallel experiments, we also measured single-cycle infectivities in TZMbl 
indicator cells, which display #-galactosidase activity after successful infection. Similar 
to the GHOST cell infectivity assay, the TZMbl assay showed decreased infectivity of 
virions produced in the absence of UPF1 (Appendix 4.3A).  
To test whether this effect on infectivity is specific only to virus produced in 293T 
cells, we also depleted endogenous UPF1 in HeLa cells producing single-cycle virions 
lacking Vpr-, which mitigates the cytopathic effect of the NL4-3 virus (Vpr+) on HeLa 
cells. We observed that virions produced in HeLa cells with UPF1 knockdown also had 
decreased infectivity (Appendix 4.3B), suggesting that this involvement of UPF1 in HIV-
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Figure 4.5 HIV-1 single cycle infectivity involves endogenous UPF1 but not UPF2 in 
virus-producing cells. 293T cells were transfected with the indicated siRNA, 0.76 µg 
pNL4-3 env-, and 0.38 µg SR"NL4-3 env and washed the next day. Two days post-
transfection, virus supernatant was harvested and quantified by p24 ELISA prior to 
infection of GHOST CD4 CXCR4 cells with equivalent amounts of virus particles. 
Infected target cells were fixed and analyzed by FACS 2 days p.i. (A) Left panel, 
immunoblot of total cell lysates of virus-producing 293T cells to assay depletion of 
UPF1; right panel, immunoblot of total cell lysates of virus-producing 293T UPF2 to 
assay for depletion of UPF2. (B)  FACS analysis for single-cycle infectivity assay 
performed on GHOST CD4 CXCR4 for virions produced when UPF1 is depleted. (C) As 
above, FACS analysis for single-cycle infectivity assay for virions produced when UPF2 
is depleted. 
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1 infectivity is not limited to virions produced in the 293T cell line.   
To determine if the NMD pathway is involved, we also depleted endogenous levels of 
the UPF1-binding partner, UPF2, in a similar experiment (Figure 4.5A, right panel), but 
we did not observe any changes in the infectivity of HIV-1 virions (Figure 4.5C). This 
indicates that the role of UPF1 in HIV-1 infectivity does not involve UPF2. 
 
5. UPF1R865A mutant does not affect viral protein expression and packaging. 
To find out whether UPF1 is required for viral protein expression and incorporation, 
we studied the effect of the dominant negative UPF1R865A mutant on the major viral 
polyprotein products: Gag, Gag-Pol, and Env. For Gag, we looked at Pr55, p41, p25, and 
p24 levels, because decreased levels in the viral protease-processed Gag proteins 
(p25/p24) and increased levels in unprocessed Gag (Pr55) or partially processed Gag 
(p41) would indicate a processing defect, resulting in immature virions that are less 
infectious. Looking at cellular levels of Gag (Figure 4.6A, left panel), we observe that the 
only effect of UPF1R865A is a slight decrease in cell-associated p24/p25 levels but without 
any significant accumulation in Pr55 or p41. Likewise, the virion lysate (Figure 4.6A, 
right panel) also shows only a slight decrease in p24 levels.  
Additionally, assaying for particle production by p24 ELISA shows a slight decrease 
(~30%) when overexpressing HA-UPF1R865A in virus-producing cells (Figure 4.6B). 
However, particle production after UPF1 depletion is not severely affected (Figure 4.6D). 
This may indicate that the decreased p25/p24 seen with UPF1R865A transfection   
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Figure 4.6 Effect of UPF1 on virus production, viral protein expression and viral 
incorporation. (A) 293T cells were transiently transfected with proviral DNA and HA-
UPF1 or mutant UPF1R865A. Purified virions and total cell lysates were analyzed by 
Western blotting with anti-CA serum, anti-HA and anti-actin antibodies. (B) Virus 
production in the presence of empty vector, HA-UPF1, or mutant UPF1R865A was 
measured by p24 ELISA. (C) 293T cells were transfected as above and virions were 
purified after adjusting for CA content, as assayed on p24 ELISA. Immunoblotting for 
integrase (read-out for Gag-Pol), gp120, and gp41 were performed. (D) Virus production 
after UPF1 depletion in virus-producing cells, as assayed by p24 ELISA. Corresponding 
cell lysates were immunoblotted for Gag, UPF1, and actin.  
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may be an artefact due to exogenous protein overexpression. 
To determine if UPF1 affects the packaging of other translated viral proteins, we 
assayed for integrase (IN, as a read-out for Gag-Pol), gp120, and gp41 in virions 
normalized for the amount of viral particles. In Figure 4.6C, we show that there is no 
appreciable difference in IN, gp120, and gp41 levels upon overexpression of HA-
UPF1R865A, compared to wild-type HA-UPF1 or empty vector. These results suggest that 
UPF1R865A does not significantly affect viral protein expression and packaging into 
virions. 
 
6. UPF1R865A mutant does not affect viral genomic RNA integrity or packaging 
into virions.  
Since UPF1 is an RNA binding protein and UPF1R865A potentially loses its capacity to 
bind RNA (Cheng et al. 2007), we wanted to determine whether overexpression of HA-
UPF1R865A would affect genomic RNA incorporation in the virions. To study this, we co-
expressed HA-UPF1 or HA- UPF1R865A and proviral DNA in 293T cells, collected viral 
supernatants and purified virions through a sucrose cushion (Figure 4.7B). We extracted 
viral RNA, reverse transcribed this, then assayed the viral cDNA using Sybr Green 
quantitative PCR with primers targeting only the full-length viral RNA (i.e. genomic) and 
not the 4kb or 2 kb viral RNAs (spliced). These primers can differentiate the genomic 
RNA since they target the location of the major splice donor site, which is intact in full-
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Figure 4.7 UPF1R865A does not affect viral genomic RNA incorporation or integrity. 
293T were transfected with proviral DNA and 0.2 µg wild-type HA-UPF1 or mutant HA-
UPF1R865A. The same volume of virus supernatant were purified, RNA was extracted 
from virions, reverse transcribed, and assayed by Sybr Green using primers specific for 
full-length, genomic viral RNA. Copy numbers were normalized by viral particle amount 
(p24).  
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length viral RNA (Figure 4.7A). As negative controls, we utilized RNA samples that 
were not reverse transcribed (-RT, Figure 4.7C), and these were run alongside our  
+RT samples during quantitative PCR. We also used a Gag stop construct (Gag is not 
translated due to a PTC engineered into the construct), and this negative control 
consistently had a signal 2 logs below our +RT samples. After normalizing for particle 
production, we observed that there is no difference in the amount of genomic RNA 
packaged in the viral particles (Figure 4.7C, average of 3 biological replicates).  
Virion-associated retroviral genomes may contain nicks (Coffin 1979), and it is 
possible that UPF1 may be contributing towards maintaining HIV-1 genome integrity 
within virions. To address this, our collaborators (Christian Roy and Ogooluwa Ojelabi 
from Melissa Moore’s group) performed Northern blots to assay for the integrity of 
virion-associated viral RNA (see probe target site, Figure 4.7A). In Figure 4.7D, we 
demonstrate that overexpression of UPF1 results in slightly less nicked RNA, as shown 
by a slight decrease in the smear. However, the profile of intact and nicked RNA in the 
empty vector and HA-UPF1R865A samples did not differ. Thus, UPF1R865A has no effect 
on viral genomic RNA integrity or incorporation into nascent virions. 
 
7. UPF1R865A mutant does not affect viral entry into target cells. 
Since the late steps of the HIV-1 life cycle were unaffected by UPF1R865A, we then 
wanted to study its effects on the early steps of the life cycle. To assay for viral entry, we 
utilized a modified BLaM-Vpr assay (described in (Cavrois et al. 2002; Brandano and 
Stevenson 2012)). The reporter construct BLaM-Vpr expresses a fusion protein that  
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Figure 4.8 UPF1R865A mutant does not affect viral entry. (A) Workflow for the viral 
fusion assay. (B) Viral entry is unaffected by HA-UPF1R865A, as demonstrated by the 
BLaM-Vpr fusion assay.   
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contains the #-lactamase gene, which provides a read-out for viral entry upon addition of 
the cell-permeable dye substrate CCF4 to infected cells. The reporter gene construct also 
encodes for Vpr, which targets the recombinant fusion protein into newly-assembled 
virions. Virus stocks were prepared from 293T cells transiently transfected with either 
HA-UPF1 or HA-UPF1R865A (Figure 4.8A). After a 2-hour infection, the virus 
supernatants were washed away and replaced by the dye substrate. Infected cells were 
counted under fluorescence microscopy and values were normalized to p24 content. As 
seen in Figure 4.7B, there was no significant difference in the number of viral fusion 
events. 
 
8. UPF1R865A decreases viral reverse transcriptase products in target cells.  
We proceeded to investigate the early, post-entry events occurring in the infected 
target cells. To accomplish this, we adopted a PCR-based approach (Mbisa et al. 2009) 
with primer sets designed to assay certain steps such as early reverse transcription (RT), 
late RT, and nuclear transport. The latter step is measured by quantifying the episomal 
forms of the provirus in the nucleus known as 2-LTR circles (Mbisa et al. 2009; Sharkey 
et al. 2000). The primers for the early RT step correspond to the vDNA in Figure 1.3A, 
while the late RT step is measured with primers specific to the U5-PBS-psi region in 
Figure 1.3F. The psi region, which corresponds to the packaging signal in the viral RNA 
genome, is found near the 3’ end of the primer-binding site (PBS).  We co-transfected 
either HA-UPF1 or HA- UPF1R865A with proviral DNA in virus-producing 293T cells, 
harvested the virus supernatant, and infected GHOST CD4 CXCR4 target cells with  
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Figure 4.9 UPF1 from virus-producing cells is required at an early, post-entry step 
of the HIV-1 life cycle. (A) The overexpression of HA-UPF1R865A in virus-producing 
cells decreases RT products and 2-LTR circles in infected target cells. (B) UPF1 
depletion in virus-producing cells causes decreased viral late RT products in target cells. 
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supernatants normalized to p24 content. For early and late RT assays, we treated the 
supernatant with DNase prior to infection to remove any plasmid contamination. We also 
included “no envelope control” samples, which we considered our background signal and 
these values were subtracted from those obtained with infected samples. With qPCR, we 
found that target cells infected with viruses produced in the presence of HA- UPF1R865A 
had significantly decreased early and late reverse transcripts and, consequently, 2-LTR 
circles (Figure 4.9A) compared to cells infected with virus produced in the presence of 
wild-type HA-UPF1. These observations suggested that functional UPF1 is required at a 
post-entry step, and to confirm this notion, we also examined single-cycle virions 
produced from UPF1-depleted 293T cells. Cells infected with these virions were likewise 
assayed for late RT products. Although the depletion of UPF1 had no effect on HIV-1 
particle production, the infectivity of these particles was severely compromised. Figure 
4.9B shows that late reverse transcriptase products were decreased to ~13% of control 
levels in cells infected with virus harvested from UPF1-depleted cells. Taken together, 
our results indicate that UPF1 is required at an early, post-entry event in the HIV-1 life 
cycle.   
 
E. Discussion 
1. Helicases in HIV-1 
Several helicases have already been implicated in the HIV-1 life cycle (Chen et al. 
2012). A microarray analysis of CD4+ T cell lines showed that 34% of host cell genes 
upregulated due to HIV-1 infection were RNA helicases (van 't Wout et al. 2003). 
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Independent genome-wide screens of HeLa and 293T cell lines for HIV-1-associated 
cellular factors yielded 12 different RNA helicases, overlapping only with DDX3X 
helicase ((Brass et al. 2008; König et al. 2008; Zhou et al. 2008), summarized in (Chen et 
al. 2012)). An example of a helicase that contributes to HIV-1 replication is RNA 
Helicase A (RHA), which may be important during viral assembly, especially in shaping 
the Gag ribonucleoprotein complex (Bolinger et al. 2010; Chen et al. 2012). RHA 
interacts with Gag in a nucleocapsid-dependent manner and this interaction is diminished 
by RNase A treatment, implying an RNA-dependent interaction (Roy et al. 2006). RHA 
also binds full-length viral RNA, with 2 RHA molecules packaged per viral particle (Roy 
et al. 2006; Sharma and Boris-Lawrie 2012). Depletion of RHA leads to a defect in 
reverse transcription (Roy et al. 2006) and to diminished infectivity in primary 
lymphocytes (Bolinger et al. 2010), but with no noticeable decrease in the packaging or 
dimerization of genomic RNA in virions (Roy et al. 2006).  
It has been reported that the helicase DDX24 is also required for the packaging of 
HIV-1 genomic RNA into virions, particularly for viral RNA exported from the nucleus 
in a Rev-dependent manner (Ma et al. 2008).  
In a study by another group, the RNA helicase RH116 was found in a screen for 
host genes downregulated by the anti-HIV-1 drug Murabutide (Cocude et al. 2003). 
Overexpression of RH116 led to ~30-fold increase in HIV-1 replication, as measured by 
p24 assay, and a 3-fold increase in viral transcription (Cocude et al. 2003). This implies 
that RH116 contributes to regulating HIV-1 replication. In the same study, the authors 
reported that RH116 shares 99.5% amino acid sequence identity to melanoma 
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differentiation-associated gene-5 (MDA5) (Cocude et al. 2003), which is a member of the 
retinoic acid-inducible gene (RIG)-I-like receptor family. MDA5 detects long dsRNA 
(e.g. polyinosinic polycytidylic acid, poly I:C) and is required for inducing the interferon 
response against RNA viruses (Kato et al. 2006). 
DDX3, another RNA helicase, has been shown to be upregulated in Tat-
expressing cells and to shuttle between the nucleus and cytoplasm in association with 
CRM1 (Yedavalli et al. 2004). DDX3 may be involved in the viral RNA export pathway 
for unspliced and partially spliced viral transcripts facilitated by Rev and CRM1 
(Yedavalli et al. 2004). 
Inhibitors targeting helicases involved in HIV-1 replication to control infection 
are being explored as an alternative therapy to HAART, since cellular factors do not 
mutate as quickly as viral proteins. The first DDX3 helicase inhibitor has been reported 
by M. Radi and colleagues (Radi et al. 2012).  
 
2. Opposite effects of MOV10 and UPF1  
MOV10, a putative helicase, has been demonstrated to inhibit HIV-1 replication 
when overexpressed in virus-producing cells (Arjan-Odedra et al. 2012; Furtak et al. 
2010; Burdick et al. 2010; Wang et al. 2010), but has no appreciable effect on HIV-1 
production and infectivity when endogenous MOV10 is depleted (Burdick et al. 2010; 
Arjan-Odedra et al. 2012).  
In this study, we have shown opposite effects on HIV-1 infectivity by two related 
helicases, MOV10 and UPF1, both of which are encapsidated into virions. The 
155
overexpression of MOV10 in virus-producing cells reduces viral infectivity (Figure 4.3B) 
while overexpression of UPF1 in virus-producing cells has no effect (Figure 4.3A). 
However, overexpression of ATPase-deficient UPF1 causes decreased single cycle 
infectivity (Figure 4.3A) while ATPase-deficient MOV10 has no effect (Figure 4.3C). 
Furthermore, we have demonstrated that both MOV10 and UPF1 are incorporated into 
HIV-1 virions in a nucleocapsid-dependent manner (Figure 4.2). Our data suggest that the 
incorporation of MOV10 and UPF1 into virions and their effect on infectivity may be 
related. This will be further discussed in the section relating to future directions. 
 
3. UPF1 depletion 
Given that UPF1 is an essential protein, we have depleted UPF1 in cell lines for 
relatively short periods of time (assaying 1 or 2 days post-transfection) to determine the 
requirement of endogenous UPF1 on HIV-1 infectivity. Single-cycle infectivity assays 
demonstrated that HIV-1 virions produced in cells depleted of UPF1 have diminished 
infectivity (Figure 4.5B, Appendix 4.3A, and Appendix 4.3B). We used both GHOST 
CD4 CXCR4 cells (assaying for GFP expression by FACS: Figure 4.5B) and TZMbl 
cells (assaying for #-galactosidase activity: Appendix 4.3A, Appendix 4.3B) to confirm 
this observation. We also utilized 293T cells and HeLa cells as virus-producing cell lines. 
In our hands, endogenous UPF1 is depleted by one day post-transfection of siRNA 
(Appendix 4.1C). In a study by A. Mouland and colleagues, they have seen depletion of 
endogenous UPF1 as early as 6 hours after transfection (Ajamian et al. 2008).  
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It remains to be seen what the effect of endogenous UPF1 depletion is in infected 
primary cells producing fully replication-competent virus. Neither siRNA transfection 
using Lipofectamine 2000 nor Amaxa nucleofection worked consistently for UPF1 
depletion in peripheral blood lymphocytes (PBLs, see Appendix 4.2). Differences in 
donor characteristics may also be causing the experimental variability for UPF1 depletion 
in PBLs, since one batch (i.e. cells from one donor) would have some UPF1 depletion 5 
days post-nucleofection (Appendix 4.2B) while another batch of PBLs would have no 
knockdown seen by immunoblotting at similar time points (Appendix 4.2C). UPF1 
protein expression in cell lines (HeLa, HEK293) is comparable to peripheral blood 
mononuclear cells (PBMCs, which is comprised of PBLs, macrophages and monocytes), 
since both exhibit strong antibody staining, as reported in the Human Protein Atlas 
(www.proteinatlas.org). We have not yet compared UPF1 expression in PBLs to cell 
lines directly.  
Currently, we are optimizing conditions for UPF1 depletion in PBLs using an 
inducible shRNA against UPF1. After selecting for transduced PBLs, we have to 
maintain them in culture for five days or more to obtain sufficient amounts of virions in 
the supernatant, which will eventually be used for an infectivity assay. We are concerned 
about prolonged UPF1 depletion since this has been shown to cause non-apoptotic cell 
death in HeLa cells by 4-7 days, as reported by C. Azzalin and J. Lingner (Azzalin and 
Lingner 2006a).  
We attempted UPF1 depletion in target cells, but the siRNA transfection was poorly 
tolerated by the TZMbl cells, which are HeLa derived. Although the preliminary 
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experiment showed that the #-galactosidase read-out from the UPF1- depleted infected 
cells was not very different from si_Control-transfected cells (Appendix 4.3D), further 
work needs to be done to optimize the experimental conditions. 
 
4. Depletion of UPF1 binding partners 
We have also depleted UPF2, the UPF1-interacting adaptor protein, to determine 
whether the NMD pathway is involved in the UPF1 requirement by HIV-1. However, we 
did not detect any differences in infectivity following UPF2 knockdown in virus-
producing cells (Figure 4.5C, Appendix 4.3B), suggesting that the role of UPF1 in HIV-1 
infectivity does not involve UPF2-dependent NMD. However, we cannot rule out the 
UPF2-independent branch of NMD. A. Kulozik and colleagues have described this 
alternative NMD pathway that is UPF2-independent but UPF3-dependent (Gehring et al. 
2003).  
In vertebrates, there are 2 paralogs of UPF3: UPF3A (on chromosome 13) and 
UPF3B (or UPF3x, located on the x chromosome), with the latter being a stronger NMD 
activator (Lykke-Andersen et al. 2000). Depletion of UPF3A has no effect on UPF3B but 
depletion of UPF3B results in increased UPF3A protein levels (Chan et al. 2009). 
UPF3A, like UPF3B, binds UPF2 and this interaction also triggers NMD.  Experiments 
to determine whether UPF3-dependent NMD is involved in this UPF1 requirement by 
HIV-1, therefore, would require concomitant UPF3A and UPF3B depletion in virus-
producing cells. These experiments have not yet been done by our group. 
158
We have not looked at depletion of Stau1, another binding partner of UPF1, to 
rule out the involvement of the SMD pathway.  L. Abrahamyan and colleagues have 
studied Stau1-depleted virions (Abrahamyan et al. 2010), which showed increased UPF1 
packaging into virions and decreased viral infectivity. Since depletion of UPF1 and 
depletion of Stau1 both result in decreased viral infectivity, it would be interesting to 
explore whether both proteins function in the same pathway to facilitate HIV-1 infection. 
Also, it would be worthwhile to look at the stoichiometry of both Stau1 and UPF1 in the 
virions, since upsetting the balance of both proteins (i.e. depleting Stau1 results in 
increased UPF1 encapsidation) seems to negatively affect HIV-1. It is unknown whether 
UPF1 depletion would result in increased Stau1 packaging in virions. 
 
5. UPF1 mutant studies 
To characterize which step of the virus life cycle is affected by UPF1, we utilized 
UPF1 helicase mutants that exert a dominant negative effect on viral infectivity (Figure 
4.4). Overexpression of dominant negative UPF1R865A did not result in any defects in the 
incorporation and processing of viral proteins (Figure 4.6), or in the genomic viral RNA 
packaging (Figure 4.7C) and genomic viral RNA integrity (Figure 4.7D). This suggests 
that UPF1 might not directly interact with the HIV-1 virion-associated genomic RNA. 
While UPF1 is incorporated into virions in a NC-dependent manner, it remains to be seen 
whether UPF1 associates with the HIV-1 NC through RNA-dependent interactions.  
Overexpression of UPF1R865A in virus-producing cells did not seem to affect viral 
entry either, as measured by a viral fusion assay (Figure 4.8). However, UPF1R865A 
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overexpression in virus-producing cells severely impaired reverse transcription by 
incoming virions in newly-infected target cells (Figure 4.9A). Similarly, depletion of 
endogenous UPF1 in virus-producing cells also caused a decrease in late reverse 
transcription products in newly-infected cells (Figure 4.9B). This implies a block at an 
early, post-entry step in the viral life cycle when UPF1 is absent or nonfunctional in 
virus-producing cells, which presumably causes decreased encapsidation of wild-type 
UPF1 in virions. 
Since UPF1R865A affects viral post-entry events as early as at the beginning of 
reverse transcription (Figure 4.9A), it would be interesting to find out how UPF1 
contributes towards the virus infection at this point. The requirement of UPF1 in the 
virus-producing cells and its subsequent incorporation into nascent virions hints at a 
function wherein this host protein is in complex with viral components. A. Hulme and 
colleagues have reported that reverse transcription inhibitor Nevirapine delays uncoating, 
implying that a block or delay in reverse transcription affects the kinetics of viral 
uncoating (Hulme et al. 2011). As discussed in the Introduction chapter, N. Arhel 
proposed three current models for uncoating (Arhel 2010) and all of these depend on the 
uncoating of the viral core in a timely manner that is coordinated with reverse 
transcription and nuclear import of the proviral DNA; otherwise, it would lead to 
unsuccessful infection. Since uncoating is basically the disassembly of the viral capsid 
from the fullerene, multimeric viral core to CA monomers and the unpacking of the viral 
ribonucleoprotein complex, consisting of the two copies of viral RNA genome and 
associated proteins, it is worthwhile to explore whether this process is similar to the 
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disassembly of the NMD complex, with its requirement for the UPF1 ATPase activity 
(Franks et al. 2010). 
Prior to characterizing the effect of UPF1R865A, we also looked at the effect of 
UPF1DE636AA. While performing these assays with UPF1DE636AA, we found that the 
sequence of our UPF1DE636AA construct had additional mutations as follows: T496A, 
I377T, and E532G. We re-cloned the DE636AA construct and tested its effect on single-
cycle infectivity, which was similar to the original mutant construct UPF1DE636AA* 
(DE636AA/T496A/I377T/E532G, from hereon designated with an asterisk). We have 
included in the Appendix the earlier work we did characterizing the effect of 
UPF1DE636AA* on HIV-1 (Appendix 4.5, 4.6). We found that overexpression of 
UPF1DE636AA* in virus-producing cells does not affect Gag processing (i.e. no 
accumulation of unprocessed or partially processed Gag, Appendix 4.5A), incorporation 
of Gag-Pol, Env (Appendix 4.5C), and incorporation of genomic viral RNA (Appendix 
4.5D). There is an observable decrease in p25 and p24, both in PR+ (has viral protease, 
Appendix 4.5A) and PR- (lacks viral protease, Appendix 4.5B) viral constructs but with 
no accumulation of unprocessed or partially processed Gag, which we interpret as 
unaffected Gag processing. We also looked at the effect of UPF1DE636AA* overexpression 
in virus-producing cells on early, post-entry events in newly infected HeLa CD4 !CT 
target cells using VSV-G-pseudotyped virions. Interestingly, there is no effect at the early 
reverse transcription step but the block is apparent from the intermediate reverse 
transcription step onwards (Appendix 4.6D). In contrast, the UPF1R865A block is apparent 
in the early reverse transcription step. Why would these two mutants manifest blocks at 
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different steps? Is it due to the inherent characteristics (e.g. lack of function; also due to 
additional mutations of UPF1DE636AA*) of each mutant? Or is it due to technical 
differences in how these two batches of assays were performed? For the UPF1DE636AA*  
virions, we pseudotyped with VSV-G while we were using HeLa CD4 !CT as target 
cells, since we had not yet optimized conditions for using GHOST CD4 CXCR4 as target 
cells. For the UPF1R865A experiments, we provided HIV-1 NL4-3 Env in trans and used 
the latter cell type for target cells. It is possible that the kinetics of viral entry may differ 
between VSV-G-pseudotyped virions and virions complemented with authentic HIV-1 
Env. However, J. Thomas et al. have reported that after initiation of reverse transcription, 
efficiencies are not affected by mode of entry (Thomas et al. 2007). 
Both APOBEC3G and HIV-1 mRNP complexes have been reported to shuttle in 
different cytoplasmic foci involved in RNA metabolism such as P bodies, Staufen 
granules, and stress granules (Gallo 2003; Gallois-Montbrun et al. 2007; Kozak et al. 
2006; Wichroski et al. 2006). It is notable in this regard that the overexpression of some 
UPF1 dominant-negative mutants results in the accumulation of NMD complexes in P 
bodies (Franks et al. 2010; Cheng et al. 2010). However, UPF1R865A does not display this 
phenotype (Cheng et al. 2007), indicating that the inhibitory effects of dominant-negative 
UPF1 mutants on HIV-1 infectivity are unrelated to their effects on P body accumulation.  
 
6. Future directions and working hypothesis 
 Although RHA belongs to helicase superfamily SF2, there are similarities 
between the observations seen by previous groups after RHA depletion and the effects of 
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UPF1 depletion or of the overexpression of a dominant negative UPF1 mutant. In each 
case, genomic viral RNA encapsidation is unaffected but the infectivity of HIV-1 virions 
is nevertheless impaired, probably due to defects at the level of reverse transcription. It 
would be interesting to explore whether RHA and UPF1 perform redundant or 
complementary functions in the HIV-1 life cycle. Virion-associated RHA has been 
estimated to be 2 molecules per viral particle, as assayed by quantitative immunoblotting 
(Sharma and Boris-Lawrie 2012). With our current experimental conditions, we are 
unable to detect endogenous UPF1 in purified viral particles by immunoblotting, 
probably due to the limited sensitivity of the antibody and purity of our viral preparations 
(Sharma and Boris-Lawrie 2012).  Alternatively, purified virions can be analyzed by 
mass spectrometry to determine the stoichiometry of virion-associated UPF1 and 
MOV10. 
 We have presented data on two related helicases, UPF1 and MOV10, which 
manifest opposite effects on HIV-1 infectivity. We would like to propose that: 1) UPF1 is 
crucial to the HIV-1 life cycle and 2) MOV10 restriction is due to its ability to displace 
UPF1 in virions. In other words, MOV10 overexpression in virus-producing cells results 
in increased encapsidation of MOV10 in virions, crowding out UPF1 and consequently, 
impairing infectivity. Similarly, the overexpression of dominant-negative UPF1 mutants 
limits the pool of functional UPF1 that can be packaged into virions. This model would 
predict that the depletion of UPF1 results in increased MOV10 incorporation? We can 
test this hypothesis by assaying for virion-associated UPF1 and MOV10 in the conditions 
shown in Figure 4.10. For instance, the overexpression of UPF1 may result in increased 
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packaging of UPF1 in virions. However, since UPF1 is required by HIV-1 during the 
next round of infection, this is not detrimental to the virus (Figure 4.10, upper left panel). 
On the other hand, when MOV10 is overexpressed in virus-producing cells, more 
MOV10 is packaged in virions, resulting in the elimination of UPF1 incorporation 
(Figure 4.10, upper right panel). This, however, would result in noninfectious virions due 
to the lack of UPF1. We would like to propose assaying virions after UPF1 depletion 
(Figure 4.10, middle panel) and after UPF1 mutant overexpression (Figure 4.10, lower 
panel) to determine which predicted outcome is correct, as illustrated by the viral cores in 
the diagram. 
 Why does the MOV10 ATPase-deficient mutant have no effect on infectivity? 
Either the MOV10 mutant is not packaged as efficiently as the wild-type MOV10 or our 
displacement hypothesis is wrong and the underlying mechanism is not due to whether 
there is enough UPF1 in the virions. 
To pinpoint the mechanism of action of UPF1 in the post-entry step of the viral 
cycle, we would also like to propose measuring the kinetics of the post-entry steps 
(uncoating and stability of the reverse transcription complex (RTC)) using an assay 
developed by V. Arfi and colleagues (V. Arfi, et al. J Virol 2009). In addition, an in situ 
uncoating assay (A. Hulme, et. al. PNAS 2011) would reveal whether UPF1 is required at 
this particular step. It is possible that UPF1 is incorporated with the RTC in the viral core, 
assisting in the uncoating and/or reverse transcription of the viral genome by performing 
a translocase function, such as removing associated viral or cellular proteins from the 
viral genome to allow reverse transcription to proceed.  
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 UPF1 is probably not in an activated state when incorporated into virions  (i.e. 
RNA-bound state of S. Chakrabarti et al.’s model of UPF1 activation (Chakrabarti et al. 
2011)). Which binding partner activates UPF1 in the context of HIV-1? UPF2 depletion 
does not affect infectivity, suggesting that UPF2 is not involved in this pathway. There is 
some evidence from A. Mouland’s group suggesting that Stau1 may possibly play this 
role. Stau1 depletion leads to increased UPF1 encapsidation but decreased infectivity 
(Abrahamyan et al. 2010). It is possible that despite the increased amount of virion-
associated UPF1, this protein may be inactive due to lack of Stau1, contributing to the 
decreased viral infectivity. Further experiments need to be done to confirm this. 
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Figure 4.10 Proposed hypothesis for future experiments. UPF1 overexpression does 
not have a deleterious effect on infectivity, which indicates that cellular UPF1 levels do 
not affect assembly of virions or increased UPF1 packaging into virions does not affect 
infectivity, provided that binding partner Stau1 is not depleted (upper left panel). MOV10 
overexpression on the other hand, may increase packaging of MOV10 in virions, which 
may displace UPF1 (upper right panel). UPF1 depletion is detrimental to the virus, 
probably either due to lack of packaged UPF1 or increased packaging of MOV10 (middle 
panel). Overexpression of a dominant negative UPF1 may increase packaging of this 
nonfunctional protein, or may block packaging of any UPF1 or over-packaging of 
MOV10 (lower panel).  
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Appendix for Chapter IV 
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Appendix 4.1 Depletion of UPF1 in cell lines. (A) Lipofectamine 2000 transfection of 
293T cells with two different siRNAs targeting UPF1 results in depletion of endogenous 
UPF1 levels. (B) Optimization of UPF1 siRNA concentration transfected in HeLa cells. 
(C) Time-course assay of UPF1 depletion by siRNA transfection in HeLa cells. 
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Appendix 4.2 Depletion of UPF1 in primary cells. (A) Lipofectamine 2000 transfection 
of siRNAs against UPF1 in activated peripheral blood lymphocytes (PBLs) does not 
deplete endogenous protein levels. (B) Time-course assay for Amaxa nucleofection of 
si_UPF1. (C) Amaxa nucleofection and NL4-3 infection of PBLs. 
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Appendix 4.3 #-galactosidase assay for TZMbl indicator cells to demonstrate single 
cycle infectivity of HIV-1. (A) UPF1 depletion in 293T virus-producing cells decrease 
single cycle infectivity of NL4-3 virus in TZMbl. (B) UPF1 depletion in HeLa virus-
producing cells decreases single cycle infectivity of NL4-3 Vpr- virus. (C) UPF2 
depletion in 293T virus-producing cells does not affect single cycle infectivity. (D) UPF1 
depletion of TZMbl target cells did not affect single cycle infectivity. 
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Appendix 4.4 Endogenous MOV10 levels. (A) Endogenous MOV10 levels in 
untransfected 293T and TZMbl cell lines. (B) Endogenous MOV10 levels are unaffected 
by UPF1 depletion in 293T cells. (C) Endogenous MOV10 levels with overexpression of 
UPF1 wild-type and UPF1R865A mutant proteins. 
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Appendix 4.5 Biochemical characterization of HIV-1 virions produced with the 
overexpression of UPF1DE636AA*. (A) Gag processing is unaffected by overexpression of 
UPF1DE636AA* but p25/p24 levels are decreased. (B) Overexpression of UPF1DE636AA* 
results in slight defect of viral release of protease-deficient virions. (C) Incorporation of 
Gag-Pol (assayed by integrase, IN) and Env (assayed by gp41) are unaffected by 
overexpression of UPF1DE636AA*. (D) Levels of virion-associated genomic RNA are 
unaffected by overexpression of UPF1DE636AA* in virus-producing cells. 
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Appendix 4.6 VSV-G-pseudotyped NL4-3 virions produced with the overexpression 
of UPF1DE636AA*. (A) Uninfected TZMbl cells contain the HIV-1 LTR and are 
inappropriate target cells for the 2-LTR assay. (B) Decreased single cycle infectivity of 
VSV-G-pseudotyped virions produced in the presence of UPF1DE636AA*. (C) Slight 
decrease in p25/p24 upon overexpression of UPF1DE636AA upon co-transfection of VSV-G 
construct. (D) Assay for early, post-entry events using HeLa CD4 !CT cell line as target 
cells upon overexpression of UPF1DE636AA*. 
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Appendix 4.7 Overexpression of active Nedd4LC2(-) rescues the decrease in p25/p24 
in virus-producing cells when UPF1DE636AA* is co-expressed. (A) Virions lacking the 
DTAP motif exhibit a block in Gag processing manifested as decreased p24 protein 
levels and accumulation of p25 proteins. This late block is rescued by overexpression of 
active Nedd4LC2(-), as seen in lanes 2 and 4, left and right panels. (B) Co-expression of 
UPF1DE636AA* results in decreased Gag p25 and p24 protein levels (lane 2), which is 
rescued by overexpression of active Nedd4LC2(-), lanes 4 and 6. 
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